Abstract is: Climacteric is a bimonthly peer-reviewed medical journal that covers all aspects of aging in women, especially during the menopause. As the official journal of the International Menopause Society, Climacteric also publishes position statements and workshop proceedings from the society. Climacteric was established in 1998. According to the Journal Citation Reports, the journal has a 2014 impact factor of 2.264. The editors-in-chief are Anna Fenton (Christchurch Women's Hospital) and Nick Panay 'Queen Charlotte's and Chelsea Hospital).
| scientific journal | Q5633421 |
| medical journal | Q16024164 |
| P8375 | Crossref journal ID | 28398 |
| P1250 | Danish Bibliometric Research Indicator (BFI) SNO/CNO | 5304 |
| P1058 | ERA Journal ID | 15907 |
| P646 | Freebase ID | /m/07s60hm |
| P8903 | HAL journal ID | 11734 |
| P236 | ISSN | 1369-7137 |
| 1473-0804 | ||
| P7363 | ISSN-L | 1369-7137 |
| P1277 | JUFO ID | 53530 |
| P4730 | Mir@bel journal ID | 21388 |
| P1055 | NLM Unique ID | 9810959 |
| P243 | OCLC control number | 628845631 |
| P856 | official website | http://www.informahealthcare.com/cmt |
| http://www.tandfonline.com/loi/icmt20 | ||
| P10283 | OpenAlex ID | S110024640 |
| P3181 | OpenCitations bibliographic resource ID | 841 |
| P7662 | Scilit journal ID | 2586284 |
| P1156 | Scopus source ID | 19505 |
| P495 | country of origin | United Kingdom | Q145 |
| P1240 | Danish Bibliometric Research Indicator level | 1 | |
| P571 | inception | 1998-01-01 | |
| P8875 | indexed in bibliographic review | Scopus | Q371467 |
| Science Citation Index Expanded | Q104047209 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | menopause | Q177708 |
| P123 | publisher | Informa | Q680946 |
| P1476 | title | Climacteric | |
| Climacteric |
| Q73100121 | 'Executive summary of the Stages of Reproductive Aging Workshop (STRAW)': not less, but more confusion |
| Q91035011 | 'Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause': pelvic organ prolapse classification issues |
| Q82158607 | 'Ma Nishtana' |
| Q37812132 | 'PROFOX'--the post HRT nightmare |
| Q77811497 | (Greetings to Japan) |
| Q47868183 | -643C > T RANKL gene polymorphism is associated with osteoporosis in Tunisian postmenopausal women |
| Q39188908 | 0.5 vs. 1.0 mg estradiol in combination with drospirenone for the treatment of hot flushes. |
| Q46877678 | 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women |
| Q94916189 | 17β-Estradiol improves osteoblastic cell function through the Sirt1/NF-κB/MMP-8 pathway |
| Q47264266 | 17β-Estradiol induces proliferation of endometrial NK cells (CD56+) in postmenopausal women |
| Q47826734 | 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. |
| Q47911973 | 75 years on: a tribute to the contribution of Fuller Albright |
| Q46714003 | 8th Pieter van Keep Memorial Lecture. Estrogen and bone: have we completed a full circle? |
| Q35113759 | A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. |
| Q77803113 | A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone |
| Q41154612 | A Commentary on a recent update of the ovarian cancer risk attributable to menopausal hormone therapy |
| Q30235315 | A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling |
| Q39064611 | A brief history of the International Menopause Society. |
| Q77803019 | A cohort study of hormone replacement therapy given to women previously treated for breast cancer |
| Q44176180 | A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer |
| Q44982963 | A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolon and continuous combined estrogen-progestogen treatment. |
| Q45118177 | A comparison of acupuncture and oral estradiol treatment of vasomotor symptoms in postmenopausal women |
| Q46877662 | A comparison of estradiol levels between women with a hysterectomy and ovarian conservation and women with an intact uterus. |
| Q46343835 | A comparison of hormone therapies on the urinary excretion of prostacyclin and thromboxane A2. |
| Q92577290 | A comparison of three outcome measures of the impact of vasomotor symptoms on women's lives |
| Q38200109 | A critical review of traditional Chinese medicine use amongst women with menopausal symptoms. |
| Q80122689 | A decade of swings and arrows |
| Q38023908 | A decade post WHI, menopausal hormone therapy comes full circle--need for independent commission |
| Q34656064 | A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder |
| Q77811518 | A general practice pilot audit study to assess advice and treatment offered to women following hysterectomy |
| Q45785676 | A global consensus statement on menopause hormone therapy--aims, aspirations and action points |
| Q37923980 | A guide to the treatment of depression in women by estrogens |
| Q48557490 | A longitudinal population study of climacteric symptoms and their treatment in a random sample of Swedish women |
| Q44982965 | A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen |
| Q93036429 | A menopause survey of women with benign breast disease history in northwest China |
| Q39199598 | A multicentric study regarding the use of hormone therapy during female mid-age (REDLINC VI). |
| Q39267153 | A negative view of menopause: does the type of symptom matter? |
| Q37157356 | A new route of synthesis of estetrol |
| Q89929543 | A pilot study: estradiol/progesterone effect on cervico-vaginal cytokines in premenopause and postmenopause |
| Q38226731 | A practitioner's toolkit for managing the menopause. |
| Q47942953 | A prospective study of DT56a (Femarelle®) for the treatment of menopause symptoms |
| Q48470838 | A prospective study of outcomes after hysterectomy in mid-aged Australian-born women |
| Q80676817 | A prospective, randomized, double-blind, placebo-controlled study on the influence of a hormone replacement therapy on skin aging in postmenopausal women |
| Q53141728 | A randomized, double-blind, placebo-controlled study of the effect of a Chinese herbal medicine preparation (Dang Gui Buxue Tang) on menopausal symptoms in Hong Kong Chinese women. |
| Q39165724 | A randomized, double-blind, placebo-controlled trial of Schisandra chinensis for menopausal symptoms |
| Q43970316 | A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability |
| Q37638712 | A review of the cardiovascular and breast actions of drospirenone in preclinical studies |
| Q53347348 | A role for estrogen in the primary prevention of Alzheimer's disease. |
| Q53432202 | A scent of a woman. |
| Q53377586 | A simple anthropometric tool for the assessment of pre-sarcopenia in postmenopausal women. |
| Q43434606 | A single hormonal test predicts breast cancer risk up to 20 years later |
| Q79330260 | A study of women on long-term hormone replacement therapy and their attitude to suggested cessation |
| Q93041982 | A study protocol of vaginal laser therapy in gynecological cancer survivors |
| Q81681876 | A survey among breast cancer survivors: treatment of the climacteric after breast cancer |
| Q34573300 | A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. I. An assessment of the quality of randomized trials published between 1977 and 1995. |
| Q34573282 | A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects |
| Q73100093 | A tale of two studies: reflections on WHI and WISDOM |
| Q96822178 | ACTN3 R577X polymorphism related to sarcopenia and physical fitness in active older women |
| Q57599356 | ADRB3andPPARγ2gene polymorphisms and their association with cardiovascular disease risk in postmenopausal women |
| Q39151784 | Abnormal uterine bleeding in perimenopause |
| Q88425163 | Abstracts for 15th World Congress on Menopause |
| Q74248798 | Abstracts from the 10th World Congress on the Menopause. Berlin, Germany, June 10-14, 2002 |
| Q81260399 | Abstracts of the 11th World Congress on the Menopause |
| Q81186101 | Abstracts of the 12th World Congress on the Menopause |
| Q84383457 | Abstracts of the 13th World Congress on the Menopause. June 8-11, 2011. Rome, Italy |
| Q95353699 | Abstracts of the 14th World Congress on Menopause, May 1-4, 2014, Cancun, Mexico |
| Q39411782 | Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate |
| Q43244413 | Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer |
| Q73614295 | Acronym--acrimony |
| Q84660600 | Acupuncture for hot flushes |
| Q98166188 | Acupuncture for menopausal symptoms in Chinese women: a systematic review |
| Q37360482 | Acupuncture for treating menopausal hot flushes: a systematic review |
| Q44125113 | Acupuncture improves sleep in postmenopause in a randomized, double-blind, placebo-controlled study |
| Q36939494 | Acupuncture in managing menopausal symptoms: hope or mirage? |
| Q46470154 | Acupuncture may cause hepatotoxicity in patients in climacteric |
| Q84289015 | Acupuncture-ameliorated menopausal symptoms: single-blind, placebo-controlled, randomized trial |
| Q83105641 | Acute and long-term estradiol kinetics in smoking postmenopausal women |
| Q77803047 | Acute effects of a surgical menopause on serum concentrations of lipoprotein(a) |
| Q44624264 | Acute effects of tibolone on cerebral vascular reactivityin vitro |
| Q36276334 | Added benefits of drospirenone for compliance |
| Q44355116 | Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-being |
| Q48573732 | Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene. |
| Q41704724 | Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter |
| Q83394781 | Adherence to osteoporosis medications |
| Q48891033 | Adherence with hormone replacement therapy in menopause |
| Q36502941 | Adipose tissue, insulin resistance and low-grade inflammation: implications for atherogenesis and the cardiovascular harm of estrogen plus progestogen therapy |
| Q90580258 | Adjuvant endocrine therapy side-effects among postmenopausal breast cancer patients in Malaysia |
| Q46043963 | Advances in menopause research--what does the next decade hold? |
| Q38121153 | Advances in neurosteroids: role in clinical practice |
| Q91353860 | Advances in surgical strategies for prolapse |
| Q50930910 | Adverse mood effects during postmenopausal hormone treatment in relation to personality traits. |
| Q89535635 | Advertising in medical journals |
| Q77811725 | Advertising standards for complimentary medicines at the climacteric |
| Q46399464 | Age at menarche, abnormal glucose tolerance and type 2 diabetes mellitus: The Rancho Bernardo Study |
| Q84514667 | Age at menarche, age at menopause and duration of fertility as risk factors for osteoporosis |
| Q39865144 | Age at menopause and factors associated with attainment of menopause in an urban community in Ibadan, Nigeria |
| Q48228258 | Age at menopause, motives for consultation and symptoms reported by 40-59-year-old Mexican women |
| Q45014912 | Age at menopause, reproductive history and VTE risk |
| Q37778396 | Age of menopause and impact of climacteric symptoms by geographical region |
| Q41533170 | Age-related changes in the diagnostic assessment of women with severe cervical lesions |
| Q48274175 | Age-related differences in left ventricular structure and function between healthy men and women. |
| Q36305830 | Age-related prevalence of osteoporosis and fragility fractures: real-world data from an Austrian Menopause and Osteoporosis Clinic |
| Q39770268 | Age-specific anti-Müllerian hormone and electrocardiographic silent coronary artery disease |
| Q87645084 | Age-specific serum anti-Müllerian hormone levels: estimates from a large population-based sample |
| Q37610364 | Aging, menopause, cardiovascular disease and HRT. International Menopause Society Consensus Statement |
| Q51940084 | Algorithm for prescription of HRT or ERT for postmenopausal women. |
| Q128587556 | Allelic variants of the estrogen receptor genes and frailty phenotype in postmenopausal women |
| Q82512962 | Alternative regimens for endometrial protection ? Where are we now? |
| Q35605657 | Alternatives for optimal hormone replacement therapy. |
| Q36946824 | Alzheimer's disease and other neurological disorders |
| Q38871979 | Alzheimer's disease, menopause and the impact of the estrogenic environment |
| Q77819916 | Amenorrhea frequency with continuous combined hormone replacement therapy: a retrospective analysis. Menopause Study Group |
| Q88103156 | Amla prevents fructose-induced hepatic steatosis in ovariectomized rats: role of liver FXR and LXRα |
| Q40141808 | An International Menopause Society study of climate, altitude, temperature (IMS-CAT) and vasomotor symptoms in urban Indian regions |
| Q40295399 | An International Menopause Society study of vasomotor symptoms in Bangkok and Chiang Mai, Thailand |
| Q43560058 | An Iranian family with azoospermia and premature ovarian insufficiency segregating NR5A1 mutation |
| Q93205707 | An epidemiologic study of pelvic organ prolapse in postmenopausal women: a population-based sample in China |
| Q129112737 | An ethical assessment of compounded bioidentical hormone therapy |
| Q96435014 | An extended Menopause Rating Scale II: a retrospective data analysis |
| Q47225254 | An inverse relation between the Simplified Menopausal Index and biological antioxidant potential |
| Q48360111 | An investigation of discordance between subjective and physiological measures of vasomotor symptoms |
| Q96291845 | An overview of the main intrauterine pathologies in the postmenopausal period |
| Q88246717 | An unusual hazard of menopause in the workplace: a case report |
| Q37059728 | An update review of cellular mechanisms conferring the indirect and direct effects of estrogen on articular cartilage |
| Q53716534 | Analysis of differential genetic expression in endometrial polyps of postmenopausal women. |
| Q93384585 | Analysis of factors that influence the quality of sexual life of climacteric women in China |
| Q46192322 | Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients |
| Q37610408 | Androgen replacement therapy and cardiovascular function |
| Q38104425 | Androgen therapy in women, beyond libido. |
| Q38190104 | Androgens and cardiovascular disease in postmenopausal women: a systematic review. |
| Q46259259 | Androgens in relationship to cardiovascular risk factors in the menopausal transition |
| Q44278024 | Ankle stiffness in postmenopausal women: influence of hormone therapy and menopause nature |
| Q43755331 | Anti-Müllerian hormone - is it a clinically useful test? |
| Q42650962 | Antiatherogenic effects of 17 beta-estradiol and 17 alpha-estradiol and its derivative J811 in cholesterol-fed rabbits with thyroid inhibition |
| Q95790978 | Antihypertensives and breast cancer risk |
| Q53589102 | Antiresorptives and anabolic therapy in sequence or combination for postmenopausal osteoporosis. |
| Q77803105 | Apolipoprotein E phenotype associations with plasma lipoproteins and bone mass in postmenopausal women |
| Q40334476 | Apoptosis and proliferation in breast cancer cells, cultured in vitro: effects of SERMs |
| Q45045458 | Are low levels of low back pain intensity and disability associated with reduced well-being in community-based women? |
| Q38104783 | Are progestins really necessary as part of a combined HRT regimen? |
| Q46378662 | Are the benefits of low-dose estrogens really proven? |
| Q88736840 | Are we there yet? |
| Q38812465 | Are women with polycystic ovary syndrome at increased cardiovascular disease risk later in life? |
| Q51198123 | Aromatase inhibitors associated with knee subchondral bone expansion without cartilage loss. |
| Q92730636 | Artificial intelligence and women's health |
| Q92484143 | Assessing symptomatic vulvar, vaginal, and lower urinary tract atrophy |
| Q90958233 | Assessment and hormonal management of osteoporosis |
| Q90361144 | Assessment and management of B3 breast lesions with atypia: a focused review |
| Q78481783 | Assessment of bleeding patterns |
| Q37118799 | Assessment of health-related quality of life in menopause and aging |
| Q40337050 | Assessment of hot flushes and vaginal dryness among obese women undergoing bariatric surgery |
| Q84578390 | Assessment of risk factors for low bone mineral density in Brazilian postmenopausal women |
| Q90907004 | Assessment of sexual activity and menopausal symptoms in middle-aged Chinese women using the Menopause Rating Scale |
| Q44248426 | Assessment of sexuality among middle-aged women using the Female Sexual Function Index |
| Q42166397 | Associated response in bone mineral density and atherogenic lipid profile during treatment with two different selective estrogen receptor modulators: levormeloxifene and raloxifene |
| Q36928773 | Association analyses suggest the effects of RANK and RANKL on age at menarche in Chinese women. |
| Q44152249 | Association between consultations with complementary/alternative medicine practitioners and menopause-related symptoms: a cross-sectional study. |
| Q91718659 | Association between depressed mood and sexual function among mid-aged Paraguayan women |
| Q44497578 | Association between estrogen receptor gene polymorphisms and breast density in postmenopausal women |
| Q46877682 | Association between habitual physical activity and parameters of physical fitness in postmenopausal women |
| Q91314825 | Association between high levels of gynoid fat and the increase of bone mineral density in women |
| Q38476072 | Association between hormone therapy and nerve conduction study parameters in postmenopausal women |
| Q91738618 | Association between non-HDL-C/HDL-C ratio and carotid atherosclerosis in postmenopausal middle-aged women |
| Q91023313 | Association between nonalcoholic fatty liver disease and bone mineral density in postmenopausal women |
| Q85645573 | Association between periodontal changes and osteoporosis in postmenopausal women |
| Q87547081 | Association between polymorphisms in period genes and bone density in postmenopausal Korean women |
| Q92228279 | Association between rs12742784 polymorphism and hip fracture, bone mineral density, and EPHB2 mRNA expression levels in elderly Chinese women |
| Q51407439 | Association between sexual function and depression in sexually active, mid-aged, Peruvian women. |
| Q91955102 | Association of P2X7R gene with serum lipid profiles in Chinese postmenopausal women with osteoporosis |
| Q90846726 | Association of RMND1/CCDC170-ESR1 single nucleotide polymorphisms with hip fracture and osteoporosis in postmenopausal women |
| Q90958289 | Association of VDR and OPG gene polymorphism with osteoporosis risk in Chinese postmenopausal women |
| Q48925301 | Association of adipokines and estradiol with bone and carotid calcifications in postmenopausal women. |
| Q49484110 | Association of body composition with menopausal symptoms in (peri-)menopausal women |
| Q43420290 | Association of breast vascular calcifications with low bone mass in postmenopausal women. |
| Q51315653 | Association of metabolic syndrome with coronary atherosclerosis in non-diabetic postmenopausal women. |
| Q91085229 | Association of mindfulness and stress with menopausal symptoms in midlife women |
| Q48329812 | Association of objectively measured physical activity and physical fitness with menopause symptoms. The Flamenco Project. |
| Q92652155 | Association of oral estradiol dose/levels with coagulation measures in early/late postmenopausal women |
| Q90937208 | Association of serum ferritin levels with non-alcoholic fatty liver disease in postmenopausal women |
| Q50620728 | Association of serum paraoxonase concentration with serum lipid levels and bone mineral density measurements in early postmenopausal women. |
| Q39377199 | Association of serum uric acid with high-sensitivity C-reactive protein in postmenopausal women. |
| Q44766296 | Association of vitamin D deficiency with muscle strength and quality of life in postmenopausal women. |
| Q92730592 | Associations among menopausal status, menopausal symptoms, and depressive symptoms in midlife women in Hunan Province, China |
| Q38412765 | Associations between osteoporosis and coronary artery disease in postmenopausal women |
| Q58880291 | Associations between the use of complementary and alternative medications and demographic, health and lifestyle factors in mid-life Australian women |
| Q77803080 | Asymptomatic postmenopausal intrauterine fluid accumulation: characterization and significance |
| Q90958279 | Atherosclerotic disease and cardiovascular risk factors in postmenopausal breast cancer survivors: a case-control study |
| Q73939799 | Atrophic vaginitis in Filipino women |
| Q96434991 | Attitude and knowledge for menopause management among health professionals in mainland China |
| Q39254200 | Attitude of German gynecologists towards prescribing HRT before and after the WHI study |
| Q37552246 | Attitudes and approaches to vaginal atrophy in postmenopausal women: a focus group qualitative study |
| Q51058338 | Attitudes of middle-aged women to aging: contribution of the Reactions to Aging Questionnaire. |
| Q51292022 | Attitudes toward menstruation in females with schizophrenia or schizoaffective disorders in Taiwan. |
| Q56935543 | Attitudes towards and use of dietary supplementation in a sample of postmenopausal women |
| Q97684655 | Australian women's understanding of menopause and its consequences: a qualitative study |
| Q57180621 | Author's reply |
| Q91033752 | Author's reply |
| Q87294359 | Author's reply: To PMID 24990143 |
| Q95785289 | Author's reply: To PMID 25131779 |
| Q129438920 | Authorization of anastrazole to prevent breast cancer in postmenopausal women: a bad idea |
| Q57288155 | Authors' reply |
| Q87918756 | Authors' reply |
| Q117307773 | BRCA carriers after risk-reducing bilateral salpingo-oophorectomy: menopausal hormone therapy knowledge gaps, and the impact of physicians’ recommendations |
| Q85845510 | Bazedoxifene blocks AGEs-RAGE-induced superoxide generation and MCP-1 level in endothelial cells |
| Q30455905 | Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention |
| Q37698607 | Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis |
| Q90967446 | Benefit-risk profile of black cohosh (isopropanolic Cimicifuga racemosa extract) with and without St John's wort in breast cancer patients |
| Q92519570 | Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators |
| Q104751502 | Bioidentical hormones |
| Q42698182 | Bioidentical hormones: what is all the hype about? |
| Q55060038 | Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal. |
| Q38617760 | Bisphosphonate drug holidays--when, why and for how long? |
| Q79963163 | Bisphosphonate-associated osteonecrosis of the jaws |
| Q47971241 | Black cohosh improves objective sleep in postmenopausal women with sleep disturbance |
| Q80510068 | Black cohosh: a cause of abnormal postmenopausal liver function tests |
| Q92141074 | Black women with postmenopausal bleeding have lower prevalence of endometrial cancer than other ethnic groups |
| Q43989203 | Bleeding patterns and endometrial histology during administration of low-dose estradiol sequentially combined with dydrogesterone |
| Q37610380 | Blood pressure through aging and menopause |
| Q48139758 | Body image and depression |
| Q40653913 | Body roundness index and body adiposity index: two new anthropometric indices to identify metabolic syndrome among Chinese postmenopausal women |
| Q95784465 | Body-identical hormone replacement |
| Q43761870 | Bone densitometry in clinical practice: longitudinal measurements at three sites in postmenopausal women on five treatments |
| Q92521790 | Bone health in women with breast cancer |
| Q47988453 | Bone loss in premenopausal, perimenopausal and postmenopausal women: results of a prospective observational study over 9 years |
| Q40469625 | Bone mineral density at different sites and vertebral fractures in Serbian postmenopausal women. |
| Q35177420 | Bone mineral density in midlife women: the Study of Women's Health in Qatar |
| Q89373056 | Bone turnover alterations across the menopausal transition in south-eastern Chinese women [corrected] |
| Q44242882 | Bone, cartilage and hormone therapy: established concepts and future scenarios |
| Q91144278 | Bothersome menopausal symptoms amongst postmenopausal Iranian women |
| Q88246738 | Bowel cancer screening for women at midlife |
| Q114638594 | Brain fog in menopause: a health-care professional’s guide for decision-making and counseling on cognition |
| Q95822737 | Breaking news: HRT to prevent chronic conditions |
| Q51817677 | Breast arterial calcification is a predictive factor of cardiovascular disease in Brazilian postmenopausal women. |
| Q83636177 | Breast cancer and bone mineral density: the Marburg Breast Cancer and Osteoporosis Trial (MABOT II) |
| Q43932815 | Breast cancer and menopause: perceptions of diagnosis, menopausal therapies and health behaviors |
| Q84080747 | Breast cancer and postmenopausal hormone therapy |
| Q60700780 | Breast cancer in premenopausal women: recurrence and survival rates and relationship to hormone replacement therapy |
| Q83908929 | Breast cancer incidence rates in US women are no longer declining |
| Q81326945 | Breast cancer prevention |
| Q95817456 | Breast cancer risk and pretreatment estrogen levels |
| Q84937992 | Breast cancer screening--when do we start and how often should it be done? |
| Q36946802 | Breast cancer: are estrogen metabolites carcinogenic? |
| Q43622095 | Breast epithelial proliferation in postmenopausal women evaluated through fine-needle-aspiration cytology |
| Q50105670 | Breast health in developing countries |
| Q53672148 | British-Asian women's views on and attitudes towards menopause and hormone replacement therapy. |
| Q39387047 | CE/BZA effects on bone and quality of life in European postmenopausal women: a pooled analysis |
| Q46728259 | CLarifying vaginal atrophy's impact On SEx and Relationships (CLOSER) survey in South Africa |
| Q100765626 | CO2 laser and the genitourinary syndrome of menopause: a randomized sham-controlled trial |
| Q93070505 | COL1A1, CCDC170, and ESR1 single nucleotide polymorphisms associated with distal radius fracture in postmenopausal Mexican women |
| Q81946688 | CYP17 polymorphism and hot flushes in postmenopausal women |
| Q38358763 | Calcium and bone health--goodbye, calcium supplements? |
| Q37223483 | Calcium supplementation and vascular disease. |
| Q46309316 | Calcium supplementation: is there a cardiovascular risk? |
| Q82131891 | Calcium supplements and the risk of cardiovascular events |
| Q95785114 | Calcium-collagen chelate supplementation reduces bone loss in osteopenic postmenopausal women |
| Q36892327 | Can 19-nortestosterone derivatives be aromatized in the liver of adult humans? Are there clinical implications? |
| Q98153978 | Can pelvic organ prolapse in postmenopausal women be treated with laser therapy? |
| Q39162361 | Can polyacrylic acid treat sexual dysfunction in women with breast cancer receiving tamoxifen? |
| Q45354293 | Can we analyze the data more clearly by employing a different approach to estimate hot flushes? |
| Q82439912 | Can we predict the age of menopause transition? |
| Q92392880 | Cancer costs and gender: a snapshot of issues, trends, and opportunities to reduce inequities using Australia as an example |
| Q45038964 | Cancer, cohorts, confounding and consensus |
| Q37610385 | Cardiovascular aspects of menopausal hormone replacement therapy |
| Q35689924 | Cardiovascular benefits of aldosterone receptor antagonists |
| Q35689917 | Cardiovascular disease in postmenopausal women. |
| Q39175755 | Cardiovascular disease in women, is it different to men? The role of sex hormones |
| Q80087573 | Cardiovascular health and the menopause - an approach for gynecologists: an overview |
| Q36561352 | Cardiovascular health and the menopause: the gynecologist as the patients' interface |
| Q37994253 | Cardiovascular health in the menopausal woman: impact of the timing of hormone replacement therapy |
| Q37610374 | Cardiovascular risk and events in polycystic ovary syndrome |
| Q37610392 | Cardiovascular risk assessment in postmenopausal women: the role of the gynecologist |
| Q38871997 | Cardiovascular risk assessment in women - an update. |
| Q45237517 | Cardiovascular risk factors in middle-aged women and the association with use of hormone therapy: results from a population-based study of Swedish women. The Women's Health in the Lund Area (WHILA) Study |
| Q38817221 | Cardiovascular risk in climacteric women: focus on diet. |
| Q41685808 | Cardiovascular safety of conjugated estrogens plus bazedoxifene: meta-analysis of the SMART trials |
| Q90855940 | Care of the adult woman with Turner syndrome |
| Q88009510 | Carotid intima-media thickness and osteoporosis in postmenopausal women: a cross-sectional study |
| Q58087273 | Case report of the first successful cryopreserved ovarian tissue retransplantation in China |
| Q58079393 | Cause or prevention of breast cancer with estrogens: analysis from tumor biologic data, growth kinetic model and Women's Health Initiative study |
| Q99602595 | Celiac disease and bone health: is there a gap in the management of postmenopausal osteoporosis? |
| Q85069476 | Cellular and humoral immune responses after short-term oral hormone therapy in postmenopausal women |
| Q46461813 | Central adiposity and decreased heart rate variability in postmenopause: a cross-sectional study. |
| Q91127800 | Cerebrovascular reactivity after cessation of menopausal hormone treatment |
| Q52642829 | Cervical screening in HPV-vaccinated populations. |
| Q61846712 | Cessation of the WHI and WISDOM trials: a New Zealand perspective |
| Q61846717 | Cessation of the WHI and WISDOM trials: a New Zealand perspective |
| Q34285969 | Chains of evidence, mosaics of data: does estrogen 'cause' breast cancer? How would we know? |
| Q81242888 | Changes in activity level in women aged 40-80 years |
| Q39597454 | Changes in bone mineral density with age, menopausal status and body mass index in Turkish women |
| Q54379367 | Changes in bone resorption during the menopause transition. |
| Q77811753 | Changes in coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy |
| Q42167610 | Changes of menopausal hormone therapy use pattern since 2000: results of the Berlin Spandau Longitudinal Health Study |
| Q114394538 | Changes to health screening – we need to remain vigilant |
| Q37851989 | Changing disease trends in the Asia-Pacific |
| Q45062621 | Changing the conversation about hormone therapy |
| Q33710365 | Characteristics and recent evolution of menopausal hormone therapy use in a cohort of Swedish women |
| Q46332241 | Characteristics of breast cancer patients who experience menopausal transition due to treatment. |
| Q81946692 | Characteristics of external genitalia in pre- and postmenopausal women |
| Q90072541 | Chilliness in Japanese middle-aged women is associated with anxiety and low n-3 fatty acid intake |
| Q89929553 | Chinese women with 29-30 FMR1 CGG repeats have an earlier menopause |
| Q47227490 | Chinese women's symptoms: relation to menopause, age and related attitudes |
| Q85414694 | Cigarette smoking and age of menopause |
| Q48072972 | Cimicifuga racemosa extract for relieving menopausal symptoms: a randomized controlled trial. |
| Q38943998 | Circadian rhythm and menopause |
| Q90906943 | Circulating androgen levels before and after oophorectomy in premenopausal and postmenopausal women |
| Q47789226 | Circulating androgens are associated with mood disturbances in young postmenopausal women |
| Q47958476 | Circulating endothelial progenitor cells in postmenopausal women with and without coronary artery disease. |
| Q46683006 | Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women |
| Q34476755 | Circulating microparticles and endogenous estrogen in newly menopausal women |
| Q82158599 | Climacteric - The Journal of Adult Women's Health & Medicine |
| Q57910116 | Climacteric Commentaries |
| Q57988316 | Climacteric Commentaries |
| Q61786694 | Climacteric Commentaries |
| Q53793250 | Climacteric Commentaries. |
| Q43819942 | Climacteric commentaries |
| Q57988321 | Climacteric commentaries |
| Q85362905 | Climacteric commentaries |
| Q95405043 | Climacteric commentaries. Sexual activity and satisfaction in community-dwelling older women |
| Q95405062 | Climacteric commentaries. Simple ovarian cysts in postmenopausal women: scope of conservative management |
| Q48224354 | Climacteric commentaries. Better sleep but higher mortality risk |
| Q83659098 | Climacteric commentaries. Calcium and vitamin D in heart disease |
| Q95405053 | Climacteric commentaries. Cognitive behavior therapy for treatment of hot flushes |
| Q42918451 | Climacteric commentaries. Endogenous estradiol and coronary calcifications in postmenopausal women |
| Q84803368 | Climacteric commentaries. Menopause management revisited |
| Q95405058 | Climacteric commentaries. Physical activity across adulthood maintains physical capability in midlife |
| Q95763531 | Climacteric commentaries. Possible net harms of breast cancer screening |
| Q48224345 | Climacteric commentaries. SSRIs for hot flushes and insomnia |
| Q84977859 | Climacteric commentaries. Should we kill them all? |
| Q95405048 | Climacteric commentaries. Statin use and the risk for diabetes mellitus |
| Q83979730 | Climacteric commentaries. Surgical menopause and early mortality in the California Teachers Study |
| Q49056359 | Climacteric commentaries. Symptoms of depression among pre-, peri- and postmenopausal women in Turkey. |
| Q84977864 | Climacteric commentaries. The fragile-bone dispute |
| Q84977863 | Climacteric commentaries. The search for an effective non-hormonal treatment for hot flushes continues |
| Q83979714 | Climacteric commentaries. Type and timing of menopause and all-cause and cardiovascular mortality |
| Q83979722 | Climacteric commentaries. Where do women get their information about hormone therapy--and whom do/should they trust? |
| Q84977861 | Climacteric commentaries. Women's Health Initiative, osteoporosis prescribing and fracture incidence |
| Q47190093 | Climacteric modifications in body weight and fat tissue distribution |
| Q47195143 | Climacteric symptoms among Japanese women and men: comparison of four symptom checklists |
| Q47566055 | Climacteric symptoms and their relation to feminine self-concept |
| Q50743958 | Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy. |
| Q82095473 | Climacteric, physically active women ingesting their routine diet oxidize more carbohydrates than lipids |
| Q48075624 | Climacteric: past, present and future! |
| Q43841490 | Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints |
| Q48334580 | Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study |
| Q45118189 | Clinical background of women prescribed tibolone or combined estrogen + progestogen therapies: a UK MediPlus study |
| Q46877675 | Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer |
| Q35605662 | Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment. |
| Q74103920 | Clinical implications of perimenopausal steroid changes |
| Q37610411 | Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women |
| Q90793194 | Clinical management of vaginal bleeding in postmenopausal women |
| Q45933096 | Clinical parameters linked with malignancy in endometrial polyps. |
| Q53642681 | Clinical practice guidelines come to a turning point. |
| Q84780686 | Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms |
| Q34132246 | Clinically meaningful efficacy of a non-estrogen agent: re-analysis of phase-2 data evaluating MF101. |
| Q48135656 | Clinicopathological and prognostic significance of platelet count in patients with ovarian cancer |
| Q73109829 | Closure of WISDOM and combined HRT arm of WHI |
| Q84355722 | Coagulation activation and fluid retention associated with the use of black cohosh: a case study |
| Q36946820 | Cognition and cognitive aging |
| Q95817699 | Cognitive behavior therapy and hot flushes |
| Q97084008 | Cognitive behavioral therapy for menopausal symptoms |
| Q48305628 | Cognitive symptoms during the menopausal transition and early postmenopause |
| Q38011783 | Colorectal cancer in women: hormone replacement therapy and chemoprevention |
| Q47566217 | Combined effects of ovariectomy and streptozotocin-induced diabetes in the articular cartilage of rats |
| Q38485115 | Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. |
| Q90361065 | Combined intervention of 17β-estradiol and treadmill training ameliorates energy metabolism in skeletal muscle of female ovariectomized mice |
| Q81242903 | Comment on osteonecrosis of the jaws and bisphosphonates |
| Q104741344 | Comment: 'Can pelvic organ prolapse in postmenopausal women be treated with laser therapy?' |
| Q85972528 | Communicating risk and benefit to patients |
| Q81681789 | Communication-do we have a problem? |
| Q43256747 | Comparative effects of continuous combined hormone therapy and tibolone on body composition in postmenopausal women |
| Q56853910 | Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women |
| Q28257427 | Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women |
| Q37610396 | Comparative effects of conventional vs. novel hormone replacement therapy on blood pressure in postmenopausal women |
| Q44355120 | Comparative study to evaluate skin irritation and adhesion of Estradot and Climara in healthy postmenopausal women |
| Q50715984 | Comparison between phytoestrogens and estradiol in the prevention of atheroma in ovariectomized cholesterol-fed rabbits. |
| Q77826413 | Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Alora Study Group |
| Q39392997 | Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms |
| Q83261480 | Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis |
| Q36070138 | Comparison of calibrated and uncalibrated bone mineral density by CT to DEXA in menopausal women |
| Q54346519 | Comparison of combined low-dose hormone therapy vs. tibolone in the prevention of bone loss. |
| Q47785512 | Comparison of depression, anxiety, quality of life, vitality and mental health between premenopausal and postmenopausal women |
| Q77811729 | Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate |
| Q39040431 | Comparison of dual-energy X-ray absorptiometry with six quantitative ultrasonometry devices in women with hip fractures |
| Q43758091 | Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance |
| Q38946055 | Comparison of efficacy and local tolerability of estradiol metered-dose transdermal spray to estradiol patch in a network meta-analysis. |
| Q40742855 | Comparison of the effects of continuous combined and sequential combined medroxyprogesterone acetate-estradiol treatment on the proliferation of MCF-7 cells |
| Q80351478 | Comparison of the effects of two different types of calcium supplementation on markers of bone metabolism in a postmenopausal osteopenic population with low calcium intake: a double-blind placebo-controlled trial |
| Q77811714 | Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women |
| Q40624863 | Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition |
| Q43591416 | Comparison of the symptoms of menopause and symptoms of thyroid disease in Japanese women aged 35-59 years |
| Q38216680 | Complementary and alternative therapies for treatment of insomnia in women in postmenopause |
| Q46309453 | Complementary medicine in Germany |
| Q84118501 | Complementary therapies for managing the menopause: has there been any progress? |
| Q35025788 | Compliance with estrogen replacement therapy: current issues. |
| Q100729782 | Compounded bioidentical menopausal hormone therapy - a physician perspective |
| Q101151203 | Compounding for women's health: a compounder's perspective - need, regulations, and future |
| Q57180619 | Concerns about the review of vaginal progesterone and the vaginal first-pass effect |
| Q34680957 | Concordance of retrospective and prospective reporting of menstrual irregularity by women in the menopausal transition |
| Q51544036 | Concurrent use of simvastatin and estrogen--progestin therapy compared with each therapy alone for hypercholesterolemia in postmenopausal women. |
| Q92595975 | Conflicts of interest and the ICMJE disclosure form |
| Q48049054 | Conflicts of interest in government-funded studies |
| Q48038684 | Conflicts of interest in government-funded studies. A reply to red herrings |
| Q48038682 | Conflicts of interest, smoke and mirrors |
| Q46378676 | Conjugated equine estrogen, raloxifene and arterial stiffness in postmenopausal women |
| Q91955917 | Construct validity of the Menopause Rating Scale in Indonesia |
| Q40590787 | Continuation of hormone replacement therapy after hysterectomy |
| Q86849611 | Continued progression of lumbar disc degeneration in postmenopausal women |
| Q62335421 | Continuing decline in hormone therapy use: population trends over 17 years |
| Q36542363 | Contraception for the older woman: an update |
| Q38964244 | Contraception for the perimenopausal woman |
| Q82845631 | Controlling balance decline across the menopause using a balance-strategy training program: a randomized, controlled trial |
| Q95790955 | Controlling caloric intake and energy expenditure may not be enough to keep weight stable |
| Q34575162 | Controversial issues in climacteric medicine I. Cardiovascular disease and hormone replacement therapy. International Menopause Society Expert Workshop. 13-16 October 2000, royal society of medicine, London, UK. |
| Q34393271 | Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy. |
| Q47656974 | Controversies over the use of GnRH agonists for reduction of chemotherapy-induced gonadotoxicity. |
| Q82131905 | Conventional ovarian cancer screening does not reduce its related mortality in postmenopausal women |
| Q83294344 | Coronary arterial calcification and thoracic spine mineral density in early menopause |
| Q22248005 | Coronary heart disease and hormone replacement therapy after the menopause |
| Q44789969 | Coronary heart disease risk factors and menopause: a study in 1980 Tehranian women, the Tehran Lipid and Glucose Study |
| Q92392835 | Correction |
| Q95579091 | Correction |
| Q88875720 | Correction to: Langer et al., Menopausal hormone therapy for primary prevention: why the USPSTF is wrong |
| Q89708881 | Correction to: Rosano et al., Cardiovascular disease in women, is it different to men? The role of sex hormones |
| Q87681972 | Correction to: Tadayon, Abedi and Farshadbakht, Impact of pedometer-based walking on menopausal women's sleep quality: a randomized controlled trial |
| Q80204477 | Correlates of sexual functioning among mid-life women |
| Q44408211 | Correlates of sexual functioning in Italian menopausal women |
| Q43918021 | Correlates of urinary incontinence during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study |
| Q91559877 | Correlation of plasma microRNA-21 expression and bone turnover markers in postmenopausal women |
| Q87765350 | Corrigendum |
| Q43536886 | Cosmetic surgery prior to diagnosis of breast cancer |
| Q81242876 | Could androgens protect middle-aged women from cardiovascular events? A population-based study of Swedish women: The Women's Health in the Lund Area (WHILA) Study |
| Q91050401 | Cranberry, D-mannose and anti-inflammatory agents prevent lower urinary tract symptoms in women undergoing prolapse surgery |
| Q44485914 | Cross-sectional study of determinants of menopausal age and hormone replacement therapy use in Italian women |
| Q47946952 | Cross-talk between muscle and bone in postmenopausal women with hypovitaminosis D. |
| Q81317128 | Current controversies about combined hormone therapy and the relative risks to the breast and endometrium |
| Q46149673 | Current patient perceptions on the menopause: a South African perspective |
| Q91653950 | Current treatments for female primary stress urinary incontinence |
| Q47677534 | Current trends in hormone replacement therapy: perceptions and usage |
| Q40210721 | Custom-compounded bioidentical hormone therapy: why so popular despite potential harm? The case against routine use. |
| Q43722015 | Cut-off value of body fat in association with metabolic syndrome in Thai peri- and postmenopausal women |
| Q47783806 | Cyclicity of breast tenderness and night-time vasomotor symptoms in mid-life women: information collected using the Daily Perimenopause Diary |
| Q38057760 | DHEA and intracrinology at menopause, a positive choice for evolution of the human species |
| Q87283752 | DHEA replacement for postmenopausal women: have we been looking in the right direction? |
| Q86853959 | DHEA replacement for postmenopausal women: placebo or panacea? |
| Q37764342 | DHEA therapy in postmenopausal women: the need to move forward beyond the lack of evidence |
| Q86788158 | DHEA--finding a role for this enigmatic hormone |
| Q95822768 | DXA vs. QUS to predict fracture risk |
| Q51338912 | Daidzein improves insulin resistance in ovariectomized rats. |
| Q36045329 | Daniel R. Mishell Jr, MD, May 7, 1931-May 4, 2016. |
| Q48546452 | Deadly forecast |
| Q53287299 | Decision-making about hormone replacement therapy by women in England and Scotland. |
| Q50119412 | Decision-making about mammographic screening: pursuing informed choice. |
| Q47587523 | Declarations of interest and the removal of the public funding exemption |
| Q41685754 | Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy |
| Q34613150 | Defining 'relative' androgen deficiency in aging men: how should testosterone be measured and what are the relationships between androgen levels and physical, sexual and emotional health? |
| Q51017085 | Dehydroepiandrosterone in women with premature ovarian failure and Hashimoto's thyroiditis. |
| Q88106072 | Delay in estrogen commencement is associated with lower bone mineral density in Turner syndrome |
| Q38644783 | Dependency of cardiovascular risk on reproductive stages and on age among middle-aged Chinese women |
| Q83966545 | Depressed mood symptoms during the menopausal transition: observations from the Seattle Midlife Women's Health Study |
| Q50906914 | Depressed mood through women's reproductive cycle: correlation to mood at menopause. |
| Q49347736 | Depressive symptoms affect outcomes of pessary use in postmenopausal women with uterine prolapse |
| Q47393058 | Depressive symptoms and their risk factors in midlife women in the Middle East: a systematic review |
| Q34606825 | Depressive symptoms in climacteric women are related to menopausal symptom intensity and partner factors. |
| Q101578044 | Determinants of attained estradiol levels in response to oral estradiol plus progesterone therapy |
| Q44713727 | Determinants of body mass index in women around menopause attending menopause clinics in Italy |
| Q61568045 | Determinants of bone mineral density in older postmenopausal Chinese women |
| Q50740200 | Determinants of percent mammographic density in women with premature ovarian insufficiency. |
| Q48182699 | Determinants of severity of menopausal symptoms among Saudi women in Riyadh city |
| Q77811514 | Development and validation of a physical examination scale to assess vaginal atrophy and inflammation |
| Q46482717 | Development and validation of the Menopause-specific Quality of Life Scale for menopausal Thai women |
| Q82331242 | Development of a revised version of the Women's Health Questionnaire |
| Q92577344 | Diagnosis of endometriosis in the 21st century |
| Q36946790 | Diet and lifestyle in managing postmenopausal obesity. |
| Q101043642 | Dietary intake and menopausal symptoms in postmenopausal women: a systematic review |
| Q47260785 | Dietary intervention, weight change and vasomotor symptoms. |
| Q46126156 | Dietary phytoestrogen intake in mid-life Australian-born women: relationship to health variables |
| Q43654841 | Dietary phytoestrogens and estrogen inhibit experimental atherosclerosis |
| Q44835501 | Differences in clinician understanding and management of early menopause after breast cancer |
| Q43475431 | Differences in mortality between oophorectomy and ovarian conservation |
| Q85323581 | Differences in the vaginal lactobacilli of postmenopausal women and influence of rectal lactobacilli |
| Q37610407 | Different cardiovascular effects of progestins according to structure and activity |
| Q44982959 | Different cerebrovascular effects of medroxyprogesterone acetate and norethisterone acetate in the New Zealand White rabbit |
| Q36807581 | Differential effects of hormone therapy on serotonin, vascular function and mood in the KEEPS. |
| Q43841487 | Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study |
| Q83966550 | Differential prevalence of quality-of-life categories (domains) in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study |
| Q44355114 | Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women |
| Q83908938 | Direct association of 25-hydroxyvitamin D insufficiency, a preventable condition, with prior vertebral fractures |
| Q48652120 | Discontinuation of HRT, memory disorder and cerebral blood flow |
| Q41111878 | Discontinuation rates of menopausal hormone therapy among postmenopausal women in the post-WHI study era. |
| Q48666252 | Dispositional factors, coping and adaptation during menopause |
| Q80287845 | Distinct lipid/lipoprotein profiles and hormonal responsiveness in nine ethnic groups of postmenopausal Asian women: the Pan-Asia Menopause (PAM) study |
| Q77811587 | Disturbances in postural balance are common in postmenopausal women with vasomotor symptoms |
| Q39409059 | Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? |
| Q44772488 | Do extracts of oral soybean augment the trophic effect of estrogen on the rat uterus? |
| Q35924752 | Do female sex hormones initiate breast cancer? A review of the evidence |
| Q91320063 | Do we have new preventive strategies for optimizing cardiovascular health in women? |
| Q95790495 | Do women really take their osteoporosis therapy? |
| Q48468049 | Does HRT increase the risk of breast cancer? Don't forget the menopausal woman! |
| Q57180622 | Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study |
| Q48652132 | Does estrogen therapy enhance memory? |
| Q43297968 | Does exercise training prior to ovariectomy protect against liver and adipocyte fat accumulation in rats? |
| Q36060457 | Does genistein lower plasma lipids and homocysteine levels in postmenopausal women? A meta-analysis |
| Q48431760 | Does hormone therapy affect attention and memory in sleep-deprived women? |
| Q50995151 | Does hormone therapy, tibolone or raloxifene modify VEGF expression in cervical epithelial cells? |
| Q38101685 | Does mammographic density reflect the expression of breast cancer markers? |
| Q48215073 | Does menopause influence nocturnal awakening with headache? |
| Q51331879 | Does metabolic syndrome or its components differ in naturally and surgically menopausal women? |
| Q53201147 | Does retention of the ovaries improve long-term survival after hysterectomy? |
| Q83966534 | Does retention of the ovaries improve long-term survival after hysterectomy? A gynecological oncological perspective |
| Q44689419 | Does retention of the ovaries improve long-term survival after hysterectomy? Prophylactic oophorectomy |
| Q46256985 | Does retention of the ovaries improve long-term survival after hysterectomy? The validity of the epidemiological evidence |
| Q83189359 | Does routine gynecological surgery contribute to an early menopause? |
| Q39667229 | Does the menopausal status of female gynecologists affect their prescription of menopausal hormone therapy? |
| Q44431436 | Does the reproductive cycle influence sleep patterns in women with sleep complaints? |
| Q90143299 | Don't skip the methods section! Randomized controlled trials are not all the same |
| Q56986724 | Doppler flow analysis of the palmaris superficial branch of the radial artery in postmenopausal women with acroparesthesia: the role of hormone therapy. A pilot study |
| Q96582498 | Doppler ultrasonography of the ophthalmic artery in perimenopausal and postmenopausal women: a new approach |
| Q45933090 | Dose effects of oral estradiol on bone mineral density in Japanese women with osteoporosis. |
| Q47929314 | Dr Alice MacLennan. |
| Q36761429 | Drospirenone and estradiol: a new option for the postmenopausal woman |
| Q28293272 | Drospirenone and its antialdosterone properties |
| Q36276331 | Drospirenone in combination with estrogens: for contraception and hormone replacement therapy |
| Q36016412 | Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women |
| Q36761438 | Drospirenone with 17beta-estradiol in the postmenopausal woman with hypertension |
| Q46734936 | Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms |
| Q35689931 | Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. |
| Q38612952 | Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors |
| Q104103233 | Dry eye disease symptoms and quality of life in perimenopausal and postmenopausal women |
| Q47702104 | Dydrogesterone does not reverse the cardiovascular benefits of percutaneous estradiol |
| Q39332661 | Dyspareunia and lubrication in premature ovarian failure using hormonal therapy and vaginal health |
| Q83966527 | ERbeta scientific visions translate to clinical uses |
| Q85733132 | Each tissue becomes master of its sex steroid environment at menopause |
| Q40021607 | Early age of natural menopause in India, a biological marker for early preventive health programs |
| Q77811538 | Early follicular phase serum FSH as a function of age: the roles of inhibin B, inhibin A and estradiol |
| Q78491774 | Early termination of WHI estrogen-progestin trial: effect on cognitive aging and dementia risk studies |
| Q38127851 | East is east and West is west: perspectives on the menopause in Asia and The West. |
| Q40167080 | Ebola in women--what the Ob-Gyns should know |
| Q87918759 | Editor's comment |
| Q95794047 | Education and cognitive reserve |
| Q37778395 | Education and information: important tools in assessing the risks and prevention of osteoporosis fractures |
| Q129330872 | Effect and mechanism of recombinant human fibroblast growth factor 18 on osteoporosis in OVX mice |
| Q51410425 | Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. |
| Q46646681 | Effect of a gonadotropin releasing hormone analog on cerebral hemodynamics in premenopausal women |
| Q48371388 | Effect of a health education program on climacteric women |
| Q43164033 | Effect of abrupt discontinuation versus gradual dose reduction of postmenopausal hormone therapy on hot flushes. |
| Q39408981 | Effect of an estradiol gel with monthly or quarterly progestogen on menopausal symptoms and bleeding |
| Q87997973 | Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer |
| Q43196464 | Effect of conventional and new therapies on climacteric symptoms and sexual dysfunction: a concern |
| Q44312532 | Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms |
| Q51777872 | Effect of different preparations of hormone therapy on sexual dysfunction in naturally postmenopausal women. |
| Q46251429 | Effect of endogenous estradiol levels on bone resorption and bone mineral density in healthy postmenopausal women: a prospective study |
| Q51334209 | Effect of estradiol on the expression of renal sodium transporters in rats. |
| Q57599557 | Effect of estrogen therapy on vascular perlecan and metalloproteinases 2 and 9 in castrated rats |
| Q36892322 | Effect of estrogens on skin aging and the potential role of selective estrogen receptor modulators |
| Q48606046 | Effect of exercise combined with phytoestrogens on quality of life in postmenopausal women |
| Q53159543 | Effect of exercise on the auditory discrimination task in perimenopausal women: a preliminary study. |
| Q83981096 | Effect of exercise training and isoflavones on hepatic steatosis in overweight postmenopausal women |
| Q47980240 | Effect of health education combining diet and exercise supervision in Chinese women with perimenopausal symptoms: a randomized controlled trial |
| Q34479999 | Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review |
| Q46412151 | Effect of hormone replacement therapy on lipids and left ventricular function in postmenopausal smokers |
| Q52013773 | Effect of hormone replacement therapy on self-reported cognitive symptoms: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. |
| Q84485152 | Effect of hormone therapy on lean body mass, falls and fractures |
| Q39917977 | Effect of internal iliac artery ligation on ovarian blood supply and ovarian reserve |
| Q43646550 | Effect of long-term, high-dose estrogen treatment on prolactin levels: a retrospective analysis. |
| Q44644950 | Effect of menopause on cardiovascular disease and its risk factors: a 9-year follow-up study |
| Q83908932 | Effect of nitroglycerin ointment on bone density |
| Q45933093 | Effect of non-oral estrogen on risk markers for metabolic syndrome in early surgically menopausal women. |
| Q36482360 | Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy |
| Q36889050 | Effect of ovarian aging on androgen biosynthesis in a cynomolgus macaque model |
| Q40810912 | Effect of pedometer-based walking on depression, anxiety and insomnia among postmenopausal women. |
| Q77811709 | Effect of perimenopause on calcium absorption: a longitudinal study |
| Q91199042 | Effect of phytoestrogens on sexual function in menopausal women: a systematic review and meta-analysis |
| Q47351023 | Effect of porcine placental extract on the mild menopausal symptoms of climacteric women. |
| Q38635554 | Effect of primary ovarian insufficiency and early natural menopause on mortality: a meta-analysis |
| Q46877686 | Effect of pure genistein on bone markers and hot flushes |
| Q44624271 | Effect of raloxifene on sexual function in postmenopausal women |
| Q77811569 | Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women |
| Q48361254 | Effect of sesamol on the pathophysiological changes induced by surgical menopause in rodents |
| Q53060093 | Effect of short-term estrogen therapy on endothelial function: a double-blinded, randomized, controlled trial. |
| Q35018819 | Effect of statins on estrogen and androgen levels in postmenopausal women treated with estradiol |
| Q30385268 | Effect of testosterone therapy on the female voice. |
| Q51163066 | Effect of the ethanol extract of Pleurotus eryngii on bone metabolism in ovariectomized rats. |
| Q48277652 | Effect of therapeutic massage on insomnia and climacteric symptoms in postmenopausal women |
| Q80676811 | Effect of three doses of conjugated estrogens/medroxyprogesterone acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: The Pan-Asia Menopause (PAM) study |
| Q50941446 | Effect of tibolone and raloxifene on serum markers of apoptosis in postmenopausal women. |
| Q50437088 | Effect of tibolone on audiologic functions in menopausal women |
| Q44206855 | Effect of transdermal estrogen therapy on some vasoactive humoral factors and 24-h ambulatory blood pressure in normotensive postmenopausal women |
| Q44205399 | Effect of ultra-low-dose estradiol and dydrogesterone on arterial stiffness in postmenopausal women |
| Q129303404 | Effectiveness and safety of menopause treatments: pitfalls of available evidence and future research need |
| Q46330230 | Effectiveness of an integrative health-care model for climacteric-stage women. |
| Q94587958 | Effectiveness of hyaluronate-based pessaries in the treatment of vulvovaginal atrophy in postmenopausal women |
| Q41592746 | Effectiveness of red clover in alleviating menopausal symptoms: a 12-week randomized, controlled trial |
| Q91134029 | Effectiveness of the short-term use of Cimicifuga racemosa in the endothelial function of postmenopausal women: a double-blind, randomized, controlled trial |
| Q44402880 | Effects of a 12-month multi-component exercise program on the body composition of postmenopausal women. |
| Q80287875 | Effects of acupuncture and estrogens on hot flushes |
| Q34577827 | Effects of acupuncture, applied relaxation, estrogens and placebo on hot flushes in postmenopausal women: an analysis of two prospective, parallel, randomized studies |
| Q43249329 | Effects of aerobic exercise training on visceral fat and serum adiponectin concentration in ovariectomized rats. |
| Q86369936 | Effects of an aglycone-rich biotransformed soybean extract in human endothelial cells |
| Q82760795 | Effects of aromatase inhibitor on menopausal hyperplasia in a case of obesity |
| Q84233727 | Effects of balance-focused interactive games compared to therapeutic balance classes for older women |
| Q44620640 | Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women |
| Q43253442 | Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy |
| Q47555073 | Effects of black cohosh and estrogen on core body and tail-skin temperatures in ovariectomized rats by telemetric monitoring with dual thermistor probes |
| Q36761442 | Effects of blood pressure reduction on cardiovascular risk estimates in hypertensive postmenopausal women |
| Q58609745 | Effects of concurrent exercise on cardiometabolic status during perimenopause: the FLAMENCO Project |
| Q46417157 | Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women |
| Q77803014 | Effects of dietary phytoestrogens in postmenopausal women |
| Q43585847 | Effects of different doses of soy isoflavones on bone tissue of ovariectomized rats |
| Q77819913 | Effects of different hormone replacement regimens on postmenopausal women with abnormal lipid levels. Menopause Study Group |
| Q58087271 | Effects of different menopausal hormone replacement regimens on body composition in Chinese women |
| Q39581323 | Effects of different progestogens on human breast tumor cell growth |
| Q46268406 | Effects of drospirenone on cardiovascular markers in human aortic endothelial cells |
| Q83795090 | Effects of drospirenone/estradiol on steroid receptors and Bcl-2 in the postmenopausal endometrium |
| Q36276339 | Effects of drospirenone/estrogen combinations on bone metabolism |
| Q86803156 | Effects of early and late treatment with soy isoflavones in the mammary gland of ovariectomized rats |
| Q57599553 | Effects of estradiol, progestogens, and of tibolone on breast proliferation and apoptosis |
| Q85896350 | Effects of estradiol-drospirenone on menopausal symptoms, lipids and bone turnover in Chinese women |
| Q52898787 | Effects of estradiol-drospirenone on ocular and nasal functions in postmenopausal women. |
| Q46528069 | Effects of estrogen and estrogenic compounds on cognition in ovariectomized rats |
| Q51459731 | Effects of estrogen and progesterone on cerebrovascular responses to euoxic hypercapnia in women. |
| Q47882241 | Effects of estrogen therapy on age-related differences in gray matter concentration |
| Q38423386 | Effects of estrogen therapy on postmenopausal sleep quality regardless of vasomotor symptoms: a randomized trial |
| Q83414378 | Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy |
| Q39958508 | Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro |
| Q38194161 | Effects of herbal preparations on symptom clusters during the menopausal transition. |
| Q34672066 | Effects of hormone replacement therapy on cognitive aging and dementia risk in postmenopausal women: a review of ongoing large-scale, long-term clinical trials |
| Q38810278 | Effects of hormone replacement therapy on immunological factors in the postmenopausal period |
| Q44018606 | Effects of hormone replacement therapy on olfactory sensitivity: cross-sectional and longitudinal studies |
| Q36359547 | Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article |
| Q84578387 | Effects of hormone therapy on ambulatory blood pressure in postmenopausal Korean women |
| Q36946786 | Effects of hormone treatment on hemostasis variables |
| Q39186769 | Effects of imparting planned health education on hot flush beliefs and quality of life of climacteric women |
| Q51489127 | Effects of low- or high-dose hormone therapy on fasting and post-methionine homocysteine levels in postmenopausal women. |
| Q36086159 | Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. |
| Q46378694 | Effects of menopausal status on circulating calcitonin gene-related peptide and adipokines: implications for insulin resistance and cardiovascular risks. |
| Q38128381 | Effects of mind-body therapies on symptom clusters during the menopausal transition. |
| Q101124506 | Effects of non-ablative vaginal erbium:YAG laser treatment for interstitial cystitis/bladder pain syndrome: a case series (UNICORN-2 study) |
| Q48183681 | Effects of omega-3 fatty acids on bone turnover markers in postmenopausal women: systematic review and meta-analysis. |
| Q45788727 | Effects of omega-3 on metabolic markers in postmenopausal women with metabolic syndrome |
| Q91199017 | Effects of oral contraceptives on ovulation induction |
| Q87906323 | Effects of oral contraceptives on ovulation induction in in vitro fertilization patients with premature ovarian insufficiency |
| Q91791448 | Effects of ospemifene on bone in postmenopausal women |
| Q47551837 | Effects of physical and depressive symptoms on the sexual life of Turkish women in the climacteric period |
| Q28252582 | Effects of phytoestrogens derived from soy bean on expression of adhesion molecules on HUVEC |
| Q36154788 | Effects of phytoestrogens on bone mineral density during the menopause transition: a systematic review of randomized, controlled trials |
| Q44397967 | Effects of progestins on olfactory sensitivity and cognition |
| Q44206833 | Effects of progestogens on the postmenopausal breast |
| Q46259272 | Effects of raloxifene on the urethra of adult castrated female rats |
| Q42166375 | Effects of raloxifene therapy on the anticoagulant system in postmenopausal women |
| Q57053731 | Effects of red clover on perimenopausal and postmenopausal women's blood lipid profile: A meta-analysis |
| Q98936542 | Effects of royal jelly on bone metabolism in postmenopausal women: a randomized, controlled study |
| Q46489443 | Effects of soy isoflavones and mechanical vibration on rat bone tissue. |
| Q47652633 | Effects of soy isoflavones on the concentration of hyaluronic acid in the vagina of type 1 diabetic rats. |
| Q39219530 | Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women |
| Q46802795 | Effects of the addition of methyltestosterone to combined hormone therapy with estrogens and progestogens on sexual energy and on orgasm in postmenopausal women |
| Q46905068 | Effects of tibolone on blood flow resistance and intima-media thickness of the carotid arteries: effect of time since menopause |
| Q43758081 | Effects of tibolone on the endometrium |
| Q38228939 | Effects of traditional Chinese medicine on symptom clusters during the menopausal transition. |
| Q44206851 | Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus |
| Q44426069 | Effects of transdermal estrogens on endothelial function in postmenopausal women with coronary disease |
| Q47327924 | Effects of weight changes on the bone. |
| Q33953308 | Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women |
| Q44624259 | Effects on climacteric symptoms, bone and lipoprotein metabolism of hormone replacement therapy delivered by estradiol-releasing intravaginal rings: a pilot study |
| Q39418335 | Effects on menopausal symptoms and acceptability of isoflavone-containing soy powder dietary supplementation |
| Q83336918 | Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis |
| Q49342771 | Efficacy and safety evaluation of Cimicifuga foetida extract in menopausal women |
| Q38252523 | Efficacy and safety of a phyto-SERM as an alternative to hormone therapy |
| Q39191397 | Efficacy and safety of non-hormonal remedies for vaginal dryness: open, prospective, randomized trial |
| Q91358322 | Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss |
| Q44206843 | Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women |
| Q91955807 | Efficacy of oral estrogen plus testosterone gel to improve sexual function in postmenopausal women |
| Q34440747 | Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review |
| Q48226514 | Efficacy of porcine placental extract on climacteric symptoms in peri- and postmenopausal women |
| Q85323708 | Efficacy of porcine placental extract on shoulder stiffness in climacteric women |
| Q34658162 | Efficacy of porcine placental extract on wrinkle widths below the eye in climacteric women |
| Q82424772 | Efficacy of porcine placental extracts with hormone therapy for postmenopausal women with knee pain |
| Q39832281 | Efficiency of auricular acupuncture in climacteric symptoms after cancer treatments |
| Q77803065 | Electrocardiogram pattern in hypercholesterolemic women: the influence of hormone replacement therapy |
| Q86881230 | Elevated LH levels draw a stronger distinction than AMH in premature ovarian insufficiency |
| Q97556325 | Emotion regulation processes and middle-aged Japanese women's health |
| Q38163573 | Endocrine resistance in breast cancer |
| Q58079398 | Endocrinopathies and cardiopathies in patients with Turner syndrome |
| Q44967339 | Endogenous androgens and effects on body fat and insulin resistance Casson. |
| Q39368721 | Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet |
| Q54379365 | Endometrial cancer and adipokines. |
| Q37855938 | Endometrial cancer, types, prognosis, female hormones and antihormones |
| Q89797043 | Endometrial development during the transition to menopause: preliminary associations with follicular dynamics |
| Q42966057 | Endometrial effect of progesterone delivered by vaginal rings in estrogen-treated postmenopausal women |
| Q87391485 | Endometrial pathology in postmenopausal women with no bleeding |
| Q53684473 | Endometrial pathology in recurrent postmenopausal bleeding: observational study of 385 women. |
| Q85836451 | Endometrial polyp or neoplasia? A case-control study in women with polyps at ultrasound |
| Q50967090 | Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol. |
| Q74597396 | Endometrial safety |
| Q43970309 | Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17 beta-estradiol combined with sequential 5-20 mg dydrogesterone |
| Q36946805 | Endometrial safety and bleeding with HRT: what's new? |
| Q44982961 | Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen |
| Q44018615 | Endometrial safety of a transdermal sequential estradiol-levonorgestrel combination |
| Q43084103 | Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy |
| Q79324113 | Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study |
| Q84154225 | Endometrial thickness for invasive investigations in women with postmenopausal bleeding |
| Q52892204 | Endometriosis after menopause: physiopathology and management of an uncommon condition. |
| Q61965577 | Endometriosis in postmenopausal women without previous hormonal therapy: report of three cases |
| Q49791633 | Endometriosis resembling endometrial cancer in a postmenopausal patient |
| Q90978055 | Endometriosis: seeking optimal management in women approaching menopause |
| Q51762947 | Endothelial dysfunction and menopause: is exercise an effective countermeasure? |
| Q39895855 | Endothelial function and cardiovascular risk stratification in menopausal women |
| Q35317556 | Endothelial function in women of the Kronos Early Estrogen Prevention Study |
| Q95607807 | Energy balance and mortality |
| Q101124512 | Er:YAG laser in hysterectomized women with stress urinary incontinence: a VELA retrospective cohort, non-inferiority study |
| Q35772313 | Erbium laser in gynecology |
| Q51721349 | Erbium laser in gynecology: aims, aspirations and action points. |
| Q87066230 | Erratum |
| Q87114492 | Erratum |
| Q91320066 | Esmirtazapine treatment of postmenopausal vasomotor symptoms: two randomized controlled trials |
| Q44025252 | Estetrol does not bind sex hormone binding globulin or increase its production by human HepG2 cells. |
| Q37157353 | Estetrol review: profile and potential clinical applications |
| Q51721309 | Estetrol, a pregnancy-specific human steroid, prevents and suppresses mammary tumor growth in a rat model. |
| Q46606650 | Estetrol: a unique steroid in human pregnancy |
| Q43758085 | Estimation of hormone replacement therapy influence on serum galanin level in postmenopausal women |
| Q83795080 | Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women |
| Q45118185 | Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens |
| Q43970313 | Estradiol and levonorgestrel: effects on bleeding pattern when administered in a sequential combined regimen with a new transdermal patch |
| Q77811578 | Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches |
| Q81242895 | Estradiol, FSH and LH profiles in nine ethnic groups of postmenopausal Asian women: the Pan-Asia Menopause (PAM) study |
| Q37610373 | Estrogen actions in the cardiovascular system |
| Q34613157 | Estrogen and colon cancer: current issues |
| Q48301980 | Estrogen and mental illness--a new frontier |
| Q38011781 | Estrogen and progestogen effect on venous thromboembolism in menopausal women |
| Q89355082 | Estrogen and progestogen inhibit NF-κB in atherosclerotic tissues of ovariectomized ApoE (-/-) mice |
| Q81091904 | Estrogen and progestogens--different routes of administration |
| Q82131877 | Estrogen and skin |
| Q87278224 | Estrogen as a new option for prevention and treatment of breast cancer – does this need a 'time gap'? |
| Q37610405 | Estrogen dose: the cardiovascular impact |
| Q35025814 | Estrogen effects on neuroendocrine function: the new challenge of pulsed therapy. |
| Q44595144 | Estrogen modulates osteogenic activity and estrogen receptor mRNA in mesenchymal stem cells of women |
| Q85339391 | Estrogen plus progestin increase superoxide dismutase and total antioxidant capacity in postmenopausal women |
| Q37610371 | Estrogen receptor actions on vascular biology and inflammation: implications in vascular pathophysiology |
| Q82806188 | Estrogen receptor gene polymorphisms in a group of postmenopausal Turkish women: association with bone mineral density |
| Q43191183 | Estrogen replacement therapy after endometrial cancer: a survey of physicians' prescribing practice |
| Q38129452 | Estrogen therapy in gynecological cancer survivors |
| Q35025809 | Estrogen therapy: from women's choice to women's preference. |
| Q87359858 | Estrogen, menopause and joints |
| Q53663375 | Estrogen-related genes and postmenopausal osteoporosis risk. |
| Q34583150 | Estrogen: effects on normal brain function and neuropsychiatric disorders. |
| Q46606636 | Estrogenic uterovaginal effects of oral estetrol in the modified Allen-Doisy test. |
| Q35025792 | Estrogens and receptors: an evolving concept. |
| Q34573312 | Estrogens and the cardiovascular system: role of estradiol metabolites in hormone replacement therapy |
| Q36226984 | Estrogens and the skin |
| Q43558031 | Estrogens as first-choice therapy for osteoporosis prevention and treatment in women under 60. |
| Q56903211 | Ethical issues in the use of complementary medicines |
| Q46802792 | Ethnic differences in levels of bone and cartilage biomarkers and hormonal responsiveness in nine groups of postmenopausal Asian women: the Pan-Asia Menopause (PAM) study |
| Q82439918 | Eu-estrogenemia and contemporary knowledge versus Rossouw's cohort and recommendations for HRT |
| Q37963449 | Evaluation and management of depressive and anxiety symptoms in midlife |
| Q92652150 | Evaluation of CD4+CD25+FOXP3+ regulatory T cells and FOXP3 mRNA in premature ovarian insufficiency |
| Q57180618 | Evaluation of a crosswalk between the European Quality of Life Five Dimension Five Level and the Menopause-Specific Quality of Life questionnaire |
| Q39949574 | Evaluation of efficacy and safety of conjugated estrogens/bazedoxifene in a Latin American population |
| Q39949665 | Evaluation of sexuality in a Paraguayan mid-aged female urban population using the six-item Female Sexual Function Index. |
| Q42166389 | Evaluation of tibolone effect on arterial resistance in postmenopausal women |
| Q60221136 | Evidence for associations between common polymorphisms of estrogen receptor β gene with homocysteine and nitric oxide |
| Q88306647 | Evidence on the use of progesterone in menopausal hormone therapy |
| Q38011787 | Evidence-based assessment of the impact of the WHI on women's health. |
| Q81594619 | Evolution and revolution at the menopause |
| Q84043026 | Evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium |
| Q27026188 | Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging |
| Q56083838 | Executive summary: Stages of Reproductive Aging Workshop (STRAW) |
| Q48736193 | Executive summary: Stages of Reproductive Aging Workshop (STRAW). |
| Q39175741 | Exercise and nutritional approaches to prevent frail bones, falls and fractures: an update |
| Q36946794 | Exercise in the menopause - an update |
| Q95806315 | Exercise, breast size and cancer risk |
| Q47272891 | Exercise, diet, weight loss and glucose metabolism. |
| Q39294765 | Experience of hormone replacement therapy among women of Sarawak, Malaysia |
| Q48666290 | Experience of menopausal symptoms by Chinese and Canadian women |
| Q38664941 | Experience of menopause in aboriginal women: a systematic review |
| Q88797227 | Experience of menopause in women with inflammatory bowel disease: pilot study |
| Q47448297 | Experiences at menopause of women in a non-English-speaking community: a qualitative study |
| Q47554583 | Experiences of menopause, self-management strategies for menopausal symptoms and perceptions of health care among immigrant women: a systematic review |
| Q79954325 | Expression of Syndecan-1 in histologically normal breast tissue from postmenopausal women with breast cancer according to mammographic density |
| Q31044648 | Expression of adhesion molecules LFA-I and ICAM-I on osteoclast precursors during osteoclast differentiation and involvement of estrogen deficiency |
| Q46251423 | Expression of the androgen receptor and syndecan-1 in breast tissue during different hormonal treatments in cynomolgus monkeys |
| Q38613173 | FRAX and fracture prediction without bone mineral density. |
| Q49586649 | FSH to estradiol ratio can be used as screening method for mild cognitive impairment in postmenopausal women |
| Q42166353 | Factors affecting long-term adherence to hormone replacement therapy after screening for osteoporosis |
| Q50693267 | Factors affecting sexual functioning of women in the mid-life years. |
| Q39769679 | Factors affecting sexuality in older Australian women: sexual interest, sexual arousal, relationships and sexual distress in older Australian women. |
| Q39425317 | Factors associated with complementary and alternative medicine use among women at midlife. |
| Q92525996 | Factors associated with long-term pessary use in women with symptomatic pelvic organ prolapse |
| Q83981387 | Factors associated with metabolic syndrome in climacteric women of southern Brazil |
| Q37803403 | Factors associated with non-compliance with hormone therapy cessation before screening mammography |
| Q44212903 | Factors associated with reporting classic menopausal symptoms differ. |
| Q79136491 | Factors associated with the use of complementary medicine and non-pharmacological interventions in symptomatic menopausal women |
| Q61713562 | Factors associated with total cholesterol levels in women around menopause attending menopause clinics in Italy |
| Q46185275 | Factors contributing to increased serum urate in postmenopausal Japanese females |
| Q40373684 | Factors determining the use of hormonal therapy and phytotherapy in Spanish postmenopausal women |
| Q39318120 | Factors influencing women's quality of life in the later half of life. |
| Q96233863 | Factors of mineral homeostasis impairment and bone mineral density loss in women with central hypogonadism |
| Q91086820 | Factors related to muscle strength in postmenopausal women aged younger than 65 years with normal vitamin D status |
| Q38724326 | Fall prevention in postmenopausal women: the role of Pilates exercise training |
| Q81999820 | Falling is not just for older women: support for pre-emptive prevention intervention before 60 |
| Q80122698 | False alarm: postmenopausal hormone therapy and ovarian cancer |
| Q47570747 | Feelings of unattractiveness in peri- and postmenopausal women are associated with depressed mood, poor memory and unsatisfactory sexual relationships |
| Q46646676 | Femal, a herbal remedy made from pollen extracts, reduces hot flushes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study |
| Q47548380 | Female hormonal factors and osteoarthritis of the knee, hip and hand: a narrative review. |
| Q53472106 | Female pelvic floor dysfunction and estrogen therapy. |
| Q51346006 | Female sexual dysfunction is more than just a hormonal problem. |
| Q30245195 | Female sexual dysfunction post radical cystectomy and urinary diversion |
| Q73939791 | Female sexual function and dysfunction: can the Cinderella of medicine turn into a princess? |
| Q35317535 | Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial |
| Q38259422 | Female urinary incontinence: effective treatment strategies. |
| Q35772324 | Female urinary stress incontinence |
| Q38813235 | Fertility in midlife women |
| Q91955118 | Fertility preservation in women with cancer and afterward |
| Q126655636 | Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis |
| Q90846721 | Fibroid management in premenopausal women |
| Q95780557 | Fibromyalgia and menopause: any link? |
| Q35772331 | First assessment of short-term efficacy of Er:YAG laser treatment on stress urinary incontinence in women: prospective cohort study |
| Q46606633 | First human exposure to exogenous single-dose oral estetrol in early postmenopausal women |
| Q44206845 | Flow resistance in carotid and middle cerebral arteries in postmenopausal women: a comparative study of tibolone and continuous combined hormone replacement therapy |
| Q97084080 | Follicle stimulating hormone and estradiol trajectories from menopausal transition to late postmenopause in indigenous Chinese women |
| Q43827197 | Food groups and risk of forearm fractures in postmenopausal women in Chengdu, China |
| Q49964080 | Foot problems in older women |
| Q45779903 | For how long should osteoporosis treatment continue? |
| Q36371627 | Fractional CO2 laser therapy: a new challenge for vulvovaginal atrophy in postmenopausal women. |
| Q38640309 | Fragility fracture risk and skeletal muscle function |
| Q53552005 | Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. |
| Q85339228 | Frequency-risk and duration-risk relations between second-hand smoke exposure and menopausal symptoms among middle-aged women in Guangzhou, China |
| Q39615279 | Future long-term trials of postmenopausal hormone replacement therapy - what is possible and what is the optimal protocol and regimen? |
| Q40610460 | GAPO syndrome: a new syndromic cause of premature ovarian insufficiency. |
| Q47948814 | Gender differences in sleep in older men and women |
| Q94524438 | Gender differences in the prevalence of vitamin D deficiency in a southern Latin American country: a pilot study |
| Q36946783 | Gender-specific characteristics of atherosclerosis in menopausal women: risk factors, clinical course and strategies for prevention |
| Q45762235 | Genetic analysis of BMP4 gene in Chinese Han female population with premature ovarian insufficiency |
| Q44884935 | Genetic profiling of fracture risk |
| Q43969410 | Genistein and exercise do not improve cardiovascular risk factors in the ovariectomized rat. |
| Q104789082 | Genistein for glycolipid metabolism in postmenopausal women: a meta-analysis |
| Q36357799 | Genitourinary syndrome of menopause in five Asian countries: results from the Pan-Asian REVIVE survey |
| Q50144500 | Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. |
| Q38242862 | Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society |
| Q38586314 | Genitourinary syndrome of the menopause--dawn of a new era? |
| Q91824779 | Getting it right: translating research into better health outcomes |
| Q48809054 | Ghost writers, vested interest and funding disclosures |
| Q93041953 | Global Consensus Position Statement on the Use of Testosterone Therapy for Women |
| Q87816992 | Global consensus statement on menopausal hormone therapy - an update |
| Q38089075 | Global consensus statement on menopausal hormone therapy. |
| Q51380858 | Glucose tolerance of premenopausal women after menopause due to surgical removal of ovaries. |
| Q93247505 | Glycine Max (L.) Merr isoflavone gel improves vaginal vascularization in postmenopausal women |
| Q100754929 | Glycyrrhizin improves bone metabolism in ovariectomized mice via inactivating NF-κB signaling |
| Q85508738 | Good news for HRT--what next? |
| Q39712403 | Greene Climacteric Scale: norms in an Australian population in relation to age and menopausal status. |
| Q45526260 | Group support to improve psychosocial well-being and primary-care demands among women with cardiac syndrome X. |
| Q53597256 | Guidelines for hormone replacement therapy of Asian women during the menopausal transition and thereafter. |
| Q81594633 | Guidelines for hormone treatment of women in the menopausal transition and beyond |
| Q80351472 | Guidelines for the hormone treatment of women in the menopausal transition and beyond |
| Q47668588 | Guizhi fuling capsule, an ancient Chinese formula, attenuates endometriosis in rats via induction of apoptosis |
| Q57180620 | Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations |
| Q77811787 | HERS and its aftermath |
| Q77803097 | HERS--a missed opportunity |
| Q53088204 | HRT and breast cancer risk: a realistic perspective. |
| Q90214510 | HRT and breast cancer: a million women ride again |
| Q77811534 | HRT and breast cancer: is there any news? A clinician's perspective |
| Q77811528 | HRT and cancer again |
| Q45287381 | HRT decreases DNA and lipid oxidation in postmenopausal women. |
| Q37847568 | HRT in difficult circumstances: are there any absolute contraindications? |
| Q61965631 | HRT in the early menopause: scientific evidence and common perceptions |
| Q37963444 | HRT misuse and the osteoporosis epidemic |
| Q28294446 | HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT |
| Q95817473 | HRT, body mass index and breast cancer risk |
| Q81493018 | HRT: does the dose matter? |
| Q44982989 | HT and WHI: the baby and the bathwater. |
| Q73457524 | HT or HRT, that is the question? |
| Q53136973 | Habitual physical activity is a meaningful predictor of well-being in mid-life women: a longitudinal analysis. |
| Q53117611 | Halleluiah, lessons from the WHI by WHI people. |
| Q123189192 | Happy Birthday, Climacterid |
| Q35119202 | Has psychosocial research on the menopause any clinical relevance? |
| Q83629916 | Has the time for the definitive, randomized, placebo-controlled HRT trial arrived? |
| Q38011779 | Have we come full circle - or moved forward? The Women's Health Initiative 10 years on. |
| Q77811719 | Headache at menopause and in hormone replacement therapy users |
| Q50721995 | Health care-seeking for menopausal problems. |
| Q48494301 | Health education intervention in early and late postmenopausal Brazilian women |
| Q96119821 | Health information needs of 1000 midlife Singaporean women |
| Q86530034 | Health knowledge, attitude, practice: the missing circle of breast cancer screening programs in Iran |
| Q81493021 | Health risks after cessation of postmenopausal hormone therapy |
| Q43574794 | Health status of hormone replacement therapy users and non-users as determined by the SF-36 quality-of-life dimension. |
| Q88948909 | Health-related quality of life and its associated factors in Chinese middle-aged women |
| Q46502235 | Health-related quality of life during hormone therapy after breast cancer: a randomized trial |
| Q48414516 | Health-related quality of life of women with menopausal hot flushes and night sweats |
| Q95271283 | Heat shock protein 90 alpha and 14-3-3η in postmenopausal osteoporotic rats with varying levels of serum FSH |
| Q91320094 | Hierarchical measurement structure in the Women's Health Questionnaire: a confirmatory factor analysis |
| Q77811784 | High resolution ultrasound assessment of the carotid artery: its relevance in postmenopausal women and the effects of tibolone on carotid artery ultrastructure |
| Q90978066 | Higher intake of dietary n-3 PUFA and lower MUFA are associated with fewer menopausal symptoms |
| Q61944710 | Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients |
| Q101124509 | Histological findings after non-ablative Er:YAG laser therapy in women with severe vaginal atrophy |
| Q48586031 | Historical milestones in the development of tibolone (Livial®). |
| Q88528713 | History of a brief time: reflections of the first female President |
| Q39462252 | History of weight cycling and future weight loss |
| Q36477867 | Homocysteine, estrogen and cognitive decline. |
| Q51052058 | Hormonal treatment and psychological function during the menopausal transition: an evaluation of the effects of conjugated estrogens/cyclic medroxyprogesterone acetate. |
| Q104751495 | Hormone replacement therapy - where are we now? |
| Q84885012 | Hormone replacement therapy after breast cancer: attitudes of women eligible in a randomized trial |
| Q39363353 | Hormone replacement therapy and WONCA/COOP functional status: a cross-sectional population-based study of women in Israel. |
| Q95823537 | Hormone replacement therapy and bias |
| Q30437754 | Hormone replacement therapy and breast density changes |
| Q102381985 | Hormone replacement therapy and cervical cancer: a systematic review of the literature |
| Q59619235 | Hormone replacement therapy and irregular bleeding |
| Q74103925 | Hormone replacement therapy and irregular bleeding |
| Q34672081 | Hormone replacement therapy and malignant melanoma: to prescribe or not to prescribe? |
| Q90967473 | Hormone replacement therapy and prevention of chronic conditions |
| Q43581949 | Hormone replacement therapy and some risk factors for breast cancer among Slovenian postmenopausal women |
| Q77803032 | Hormone replacement therapy and the skeleton: what does the evidence tell us? |
| Q34575172 | Hormone replacement therapy and venous thromboembolism |
| Q84803365 | Hormone replacement therapy in breast cancer survivors |
| Q35563738 | Hormone replacement therapy in climacteric and aging brain. International Menopause Society Expert Workshop, 15-18 March 2003, Pisa, Italy |
| Q42166384 | Hormone replacement therapy in postmenopausal women with benign fibrocystic mastopathy |
| Q35208199 | Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003. |
| Q36603657 | Hormone replacement therapy in women with past history of endometriosis |
| Q84973292 | Hormone replacement therapy prescription: a disconnect between personal and patient prescribing |
| Q73100107 | Hormone replacement therapy use over a decade in an Australian population |
| Q80917704 | Hormone replacement therapy--practical recommendations |
| Q77803053 | Hormone replacement therapy: prevalence, compliance and the 'healthy women' notion |
| Q43133482 | Hormone therapy affects plasma measures of factor VII-activating protease in younger postmenopausal women. |
| Q53757323 | Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation. |
| Q37808476 | Hormone therapy and brain tumors |
| Q36946798 | Hormone therapy and breast cancer risk |
| Q38011782 | Hormone therapy and breast cancer risk 10 years after the WHI. |
| Q90578167 | Hormone therapy and breast cancer: risk communication and the 'perfect storm' |
| Q30598177 | Hormone therapy and breast cancer: the press-release version of WHI study data |
| Q31111946 | Hormone therapy and cardiovascular disease in the early postmenopause: the WHI data revisited |
| Q85432812 | Hormone therapy and cardiovascular disease – are we back to the beginning? |
| Q43740719 | Hormone therapy and colorectal cancer |
| Q44789958 | Hormone therapy and endometrial angiogenesis |
| Q38791860 | Hormone therapy and large bowel cancer revisited |
| Q37610399 | Hormone therapy and risk of venous thromboembolism among postmenopausal women. |
| Q35689920 | Hormone therapy and the cardiovascular system: the critical role of progestins. |
| Q36909204 | Hormone therapy and the risk of stroke: perspectives 10 years after the Women's Health Initiative trials |
| Q38124919 | Hormone therapy for female sexual function during perimenopause and postmenopause: a Cochrane review. |
| Q39157162 | Hormone therapy for premature ovarian insufficiency patients with malignant hematologic diseases |
| Q46877668 | Hormone therapy for younger postmenopausal women: how can we make sense out of the evidence? |
| Q43297967 | Hormone therapy in Brazilian postmenopausal women with chronic hepatitis C: a pilot study |
| Q61864561 | Hormone therapy use after the Women's Health Initiative |
| Q36887336 | Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on. |
| Q39383552 | Hormone therapy: the European women's perspective |
| Q86036648 | Hormone variations associated with quantitative fat measures in the menopausal transition |
| Q36084247 | Hormones and depression in women |
| Q36477872 | Hormones and progeny of breast tumor cells |
| Q38249888 | Hormones and venous thromboembolism among postmenopausal women |
| Q38350761 | Hormones, herbal preparations and nutriceuticals for a better life after the menopause: part I. |
| Q38350780 | Hormones, herbal preparations and nutriceuticals for a better life after the menopause: part II. |
| Q41275781 | Hot flush severity during the menopausal transition and early postmenopause: beyond hormones |
| Q44341394 | Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women |
| Q43073625 | Hot flushes and biochemical markers for cardiovascular disease: a randomized trial on hormone therapy |
| Q77811806 | Hot flushes and other menopausal symptoms in relation to soy product intake in Japanese women |
| Q44747450 | Hot flushes still occur in a population of 85-year-old Swedish women |
| Q87701387 | Hot flushes, hormone therapy and alternative treatments: 30 years of experience from Sweden |
| Q34114657 | Hot flushes, vascular reactivity and the role of the α-adrenergic system |
| Q41414568 | How can information on the risk of breast cancer and hormone therapy be better understood? |
| Q82158687 | How low can you go? |
| Q53322438 | How menopause affects the lives of women in suburban Chandigarh, India. |
| Q78004633 | How reliably does 12-month amenorrhea define final menstrual period? Data from a longitudinal study |
| Q77811566 | How should we give progestogen? |
| Q34573324 | How significant are environmental estrogens to women? |
| Q35924753 | Human breast cell proliferation and its relationship to steroid receptor expression. |
| Q42476959 | Hypercholesterolemia accelerates bone loss in postmenopausal women |
| Q35031373 | Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety |
| Q37742631 | Hypertension in women: the role of progesterone and aldosterone |
| Q73100110 | Hysterectomy and ovarian function: levels of follicle stimulating hormone and incidence of menopausal symptoms are not affected by hysterectomy in women under age 45 years |
| Q94916183 | Hysteroscopic treatment of submucosal fibroids in perimenopausal women: when, why, and how? |
| Q94587898 | Hysteroscopy in postmenopause: from diagnosis to the management of intrauterine pathologies |
| Q28194282 | IARC monographs program on carcinogenicity of combined hormonal contraceptives and menopausal therapy |
| Q100403309 | IGF-1R/β-catenin signaling axis is implicated in streptozotocin exacerbating bone impairment in ovariectomized rats |
| Q85973074 | IMS 2014: the Congress 'highlights' |
| Q85973086 | IMS 2014: the new President's view |
| Q84660594 | IMS consensus statements - 'what is their role?' |
| Q31105720 | IMS reaction to recent breast cancer data |
| Q39488372 | IMS study of climate, altitude, temperature and vasomotor symptoms in the United Arab Emirates |
| Q34626471 | IMS updated recommendations on postmenopausal hormone therapy |
| Q45722292 | IWH: an Initiative for Women's Health with a better quality of life |
| Q47864808 | Iatrogenic menopause following gynecological malignancy: time for action! |
| Q92477474 | Identification of functional estrogen response elements in glycerol channel Aquaporin-7 gene |
| Q57135694 | Identification of the first homozygous POLG mutation causing non-syndromic ovarian dysfunction |
| Q44072002 | Identifying symptom clusters during the menopausal transition: observations from the Seattle Midlife Women's Health Study |
| Q48168454 | Imaging the brain in healthy postmenopausal users and non-users of hormone replacement therapy |
| Q38731364 | Impact of endo- and exogenous estrogens on heart rate variability in women: a review. |
| Q91571482 | Impact of endogenous and exogenous progesterone exposure on stress biomarkers: a systematic review |
| Q38845844 | Impact of insomnia on pain in postmenopausal women |
| Q86514400 | Impact of lower concentrations of phytoestrogens on the effects of estradiol in breast cancer cells |
| Q93376883 | Impact of micronized progesterone on body weight, body mass index, and glucose metabolism: a systematic review |
| Q46115727 | Impact of osteoporosis and bone fracture on health-related quality of life in postmenopausal women |
| Q40117371 | Impact of pedometer-based walking on menopausal women's sleep quality: a randomized controlled trial |
| Q42822824 | Impact of platinum-based chemotherapy on the progression of atherosclerosis |
| Q36372962 | Impact of risk-reducing salpingo-oophorectomy in premenopausal women |
| Q38235018 | Impact of smoking on estrogenic efficacy |
| Q46378668 | Impact of soy supplementation on sex steroids and vascular inflammation markers in postmenopausal women using tibolone: role of equol production capability |
| Q84043031 | Impact of surgical menopause on lipid and bone metabolism |
| Q38178431 | Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause |
| Q39659688 | Impact on quality of life related to foot health in a sample of menopausal women: a case-control observational study |
| Q36276326 | Importance of controlling blood pressure |
| Q46877689 | Importance of the progestogen added to the estrogen in hormone therapy |
| Q46141973 | Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction |
| Q51373705 | Improvement in HDL cholesterol in postmenopausal women supplemented with pumpkin seed oil: pilot study. |
| Q48039356 | Improvement of neurological disorders in postmenopausal model rats by administration of royal jelly |
| Q57598816 | Improving early detection behavior in women at risk of breast cancer: persuasion-based health monitoring model |
| Q37157360 | In vitro effects of estetrol on receptor binding, drug targets and human liver cell metabolism |
| Q37610366 | Incidence and mortality of cardiovascular disease in postmenopausal women world-wide and relevance for preventive strategies |
| Q84239458 | Increase in MMP-2 activity in overweight and obese women is associated with menopausal status |
| Q38655598 | Increased detection of co-morbidities with evaluation at a dedicated adult Turner syndrome clinic. |
| Q77811510 | Increased reduction in bone density and skin thickness in postmenopausal women taking long-term corticosteroid therapy: a suggested role for estrogen add-back therapy |
| Q113437535 | Index Medicus and MEDLINE indexing forClimacteric |
| Q74103914 | Index medicus and MEDLINE indexing for Climacteric |
| Q46873738 | Individual differences in equol production capability modulate blood pressure in tibolone-treated postmenopausal women: lack of effect of soy supplementation |
| Q83817593 | Individualized therapy for osteoporosis prevention and treatment in women under 60 |
| Q28584559 | Individually modifiable risk factors to ameliorate cognitive aging: a systematic review and meta-analysis |
| Q85362478 | Inflammation and endometrial bleeding |
| Q45237521 | Influence of a continuous combined HRT (2 mg estradiol valerate and 2 mg dienogest) on postmenopausal depression |
| Q88261292 | Influence of estrogen therapy on immune markers in postmenopausal women |
| Q43758088 | Influence of female and male sex steroids on body composition in the rabbit model |
| Q43654846 | Influence of hormone replacement therapy on postmenopausal pelvic organs |
| Q88064400 | Influence of hormone therapy or C. foetida extract on breast tenderness in postmenopausal women |
| Q49582359 | Influence of menopausal status on the main contributors of muscle quality |
| Q47264259 | Influence of menopausal symptoms on perceived work ability among women in a Nigerian University |
| Q37020192 | Influence of menopause on mood: a systematic review of cohort studies |
| Q78481778 | Influence of pregnancy and breast-feeding on quantitative ultrasonometry of bone in postmenopausal women |
| Q95559381 | Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures |
| Q46504985 | Influence of the CYP17 polymorphism on vasomotor symptoms in postmenopausal women: a pilot study |
| Q50964914 | Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner. |
| Q87039371 | Influences of teriparatide administration on marrow fat content in postmenopausal osteopenic women using MR spectroscopy |
| Q43689585 | Information and misinformation on hormone therapy and meningiomas |
| Q38883509 | Information on early menopause: is the internet the place to search? |
| Q52681809 | Innovative approaches to cervical cancer screening in low- and middle-income countries. |
| Q98936536 | Insomnia and menopause: a narrative review on mechanisms and treatments |
| Q48383139 | Insomnia in Japanese peri- and postmenopausal women |
| Q46378683 | Insulin resistance in postmenopausal women: concurrent effects of hormone replacement therapy and coffee |
| Q38982623 | Interferon beta-1b-induced postmenopausal bleeding in a patient with multiple sclerosis |
| Q99546370 | Internet Of Things and women's health |
| Q34575187 | Intrauterine application of progestins in hormone replacement therapy: a review |
| Q83228359 | Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia |
| Q52946212 | Introduction. Hormone replacement therapy and the cardiovascular system: targeting the RAAS. |
| Q96822166 | Inverse association between bone mineral density and fibrinogen in menopausal women |
| Q90675479 | Investigation of pelvic floor disorders |
| Q39161528 | Iranian postmenopausal women's experiences of treatment of symptomatic vulvovaginal atrophy |
| Q92140814 | Irisin ameliorates bone loss in ovariectomized mice |
| Q36645276 | Is HRT justified for symptom management in women at higher risk of developing breast cancer? |
| Q79184584 | Is combined estrogen/progestogen hormone therapy worth the risk? |
| Q79136483 | Is endometrial monitoring required with the use of long-term unopposed vaginal estrogen? |
| Q53633746 | Is expression of rat breast matrix components influenced by estrogen, progestins and tibolone? |
| Q73629586 | Is hormone therapy still an option for the management of osteoporosis? |
| Q34294323 | Is low-dose hormone replacement therapy for postmenopausal women efficacious and desirable? |
| Q51738113 | Is osteoporosis in postmenopausal female patients related to previous pregnancies and/or miscarriages? |
| Q43465271 | Is progesterone a synonym for medroxyprogesterone acetate? |
| Q60731185 | Is the Wii Fit™ a new-generation tool for improving balance, health and well-being? A pilot study |
| Q81317144 | Is the elevated breast cancer risk observed in the WHI study an artifact? |
| Q77811771 | Is there a proven place for phytoestrogens in the menopause? |
| Q43473598 | Is there a relationship between occupational activities and low back pain in obese, middle-aged women? |
| Q95367420 | Is yoga beneficial for menopausal symptoms? |
| Q93143392 | Isoflavones improve collagen I and glycosaminoglycans and prevent bone loss in type 1 diabetic rats |
| Q37810256 | Isoflavones: effects on bone health |
| Q86671706 | KEEPS results: a true frustration? |
| Q86915828 | KEEPS, GSM and much more |
| Q46417155 | KEEPS: The Kronos Early Estrogen Prevention Study |
| Q47181793 | Keep your weight--don't miss breakfast |
| Q91088477 | Keeping the pelvic floor healthy |
| Q38853529 | Knowledge and attitudes of health professionals regarding menopausal hormone therapies |
| Q99352987 | Knowledge and awareness toward menopause and hormone therapy among premenopausal women in Jordan |
| Q82811185 | Knowledge of Bahraini women about the menopause and hormone therapy: implications for health-care policy |
| Q43244411 | LEI (Lack of tEstosterone Impact) survey in a clinical sample with surgical menopause |
| Q44463148 | Lack of association between ESR1 gene polymorphisms and premature ovarian failure in Serbian women. |
| Q90186462 | Lack of association between early menopause and non-alcoholic fatty liver disease in postmenopausal women |
| Q77811505 | Lack of effects of transdermal estradiol on diastolic function: a randomized placebo-controlled double-blind short-term trial |
| Q56394789 | Lack of research reproducibility, the rise of open science and the need for continuing education in research methods |
| Q101124524 | Lasers in the era of evidence-based medicine |
| Q43599484 | Less mammographic density after nasal versus oral administration of postmenopausal hormone therapy |
| Q98936568 | Lessons from KEEPS: the Kronos Early Estrogen Prevention Study |
| Q79136486 | Lessons from RUTH |
| Q62026027 | Letters to the Editors |
| Q87294362 | Levonorgestrel and breast cancer risk - clarified |
| Q39404801 | Lichen sclerosus in women: a review. |
| Q52804643 | Life prevalence of hormone replacement therapy and profile of users have not changed among women with self-reported menopause in the last two decades in Porto, Portugal. |
| Q53445765 | Life satisfaction and health-related quality of life (SF-36) of middle-aged men and women. |
| Q37610393 | Lifestyle and diet in postmenopausal women |
| Q45895558 | Lifestyle and high density lipoprotein cholesterol in postmenopause. |
| Q45226716 | Light physical activity is a better determinant of lower adiposity during the menopausal transition |
| Q101124520 | Light the way for women's health |
| Q42649273 | Linking stability to demographics, strength and sensory system function in women over 40 to support pre-emptive preventive intervention |
| Q87439879 | Lipid guidelines - are we heading in the right direction? |
| Q46802785 | Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents. |
| Q40776539 | Lipid-independent effects of an estrogen-statin combination: inhibition of expression of adhesion molecules and plasminogen activator inhibitor--I in human endothelial cell cultures |
| Q44206838 | Lipids and antioxidative effects of estradiol and sequential norethisterone acetate treatment in a 3-month randomized controlled trial |
| Q81681881 | Lipids, statins and cardiovascular disease |
| Q51366152 | Liver fat accumulation may be dissociated from adiposity gain in ovariectomized rats. |
| Q37610413 | Local estrogens for quality of life and sexuality in postmenopausal women with cardiovascular disease. |
| Q48076501 | Long-term consequences of LNG-IUS vs. hysterectomy for menorrhagia |
| Q86904917 | Long-term effect of hormone therapy on bone in early menopause: vertebral fractures after 20 years |
| Q51544028 | Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women. |
| Q85414689 | Long-term effects of the Women's Health Initiative in the United States |
| Q46528062 | Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen |
| Q45237510 | Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy |
| Q50049148 | Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause |
| Q43104714 | Long-term endometrial and breast safety of a specific, standardized soy extract |
| Q47568282 | Long-term exercise training and soy isoflavones to improve quality of life and climacteric symptoms |
| Q48505898 | Long-term follow-up of acupuncture and hormone therapy on hot flushes in women with breast cancer: a prospective, randomized, controlled multicenter trial |
| Q36089352 | Long-term health consequences of premature or early menopause and considerations for management |
| Q42623255 | Long-term menopausal hormone therapy and health consequences – how to choose sides? |
| Q79963160 | Long-term trials of HRT for cardioprotection--is this as good as it gets? |
| Q90208937 | Longitudinal impact of the Women's Health Initiative study on hormone therapy use in Australia |
| Q43758095 | Longitudinal study of hormone levels and depression among women transitioning through menopause |
| Q95822210 | Looking ahead: the WHIMS-Young study |
| Q90710407 | Low bone mass is associated with carotid calcification plaque in Chinese postmenopausal women: the Chongqing osteoporosis study |
| Q40006312 | Low bone mineral density in Indian patients with fragility fractures |
| Q50609211 | Low bone mineral density is associated with breast cancer in postmenopausal women: a case-control study. |
| Q40133155 | Low bone mineral density is associated with cancer in postmenopausal women: the methodological issue |
| Q47278701 | Low intervertebral disc height in postmenopausal women with osteoporotic vertebral fractures compared to hormone-treated and untreated postmenopausal women and premenopausal women without fractures |
| Q45118181 | Low levels of endogenous estradiol protect bone mineral density in young postmenopausal women |
| Q46259264 | Low- and standard-estrogen dosage in oral therapy: dose-dependent effects on insulin and lipid metabolism in healthy postmenopausal women. |
| Q95412457 | Low-dose aspirin in primary prevention revisited |
| Q39408968 | Low-dose esterified estrogens (0.3 mg/day): long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women |
| Q36015213 | Low-dose estradiol and endothelial and inflammatory biomarkers in menopausal overweight/obese women |
| Q46069789 | Low-dose estradiol for climacteric symptoms in Japanese women: a randomized, controlled trial |
| Q34672074 | Low-dose hormone replacement therapy: effects on bone |
| Q37638709 | Low-dose hormone therapy in postmenopausal women in China |
| Q44982974 | Low-dose oral combination of 17beta-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor-1. |
| Q87392085 | Low-dose oral or non-oral hormone therapy: effects on C-reactive protein and atrial natriuretic peptide in menopause |
| Q54397044 | Lower concentrations of phthalates induce proliferation in human breast cancer cells. |
| Q90906968 | Lower expression of prestin and MYO7A correlates with menopause-associated hearing loss |
| Q46565213 | MTHFR C677T polymorphism modifies the effect of HRT on metabolic parameters in postmenopausal women |
| Q48073208 | Maca reduces blood pressure and depression, in a pilot study in postmenopausal women. |
| Q90907008 | Maintaining sexual function after pelvic floor surgery |
| Q37776521 | Male menopause: is it a real clinical syndrome? |
| Q43622091 | Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens |
| Q97551265 | Mammographic density and breast cancer screening |
| Q78004637 | Mammographic density changes in women on hormone replacement therapy |
| Q38083107 | Mammography for symptomless women--not so wise? |
| Q38619529 | Management of bone disease in women after breast cancer |
| Q37020195 | Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists |
| Q38298951 | Management of menopause in women with breast cancer |
| Q80953822 | Management of polycystic ovary syndrome in postmenopausal women: a medical black hole |
| Q38203321 | Management of pudendal neuralgia. |
| Q77803092 | Management problems. BRCA mutation, prophylactic oophorectomy and HRT |
| Q38003720 | Management strategies in SSRI-associated sexual dysfunction in women at midlife. |
| Q37823605 | Managing bone health with zoledronic acid: a review of randomized clinical study results |
| Q36561361 | Managing cardiovascular risk in menopausal women |
| Q92749176 | Managing menopausal symptoms after cancer |
| Q91601575 | Managing overactive bladder |
| Q48528965 | Managing the menopause: practical choices faced in primary care |
| Q38246710 | Managing urinary incontinence: what works? |
| Q97648163 | Managing vasomotor symptoms effectively without hormones |
| Q91968572 | Managing vasomotor symptoms in women after cancer |
| Q37157363 | Maternal and fetal estetrol levels during pregnancy |
| Q39597440 | Measurement-specific quality-of-life satisfaction during the menopause in an Arabian Gulf country |
| Q35119196 | Measuring cognition in menopause research: a review of test use |
| Q40010394 | Measuring indices of lifelong estrogen exposure: self-report reliability. |
| Q45262671 | Measuring vulvovaginal symptoms in postmenopausal women |
| Q37610367 | Mechanisms of action of estrogen receptors in vascular cells: relevance for menopause and aging. |
| Q93039620 | Medical and gynecological comorbidities in adult women with Turner syndrome: our multidisciplinary clinic experience |
| Q39295958 | Medical and patient attitude towards vaginal atrophy: the AGATA study |
| Q91127808 | Mediterranean diet is associated with bone mineral density and muscle mass in postmenopausal women |
| Q38510451 | Melatonin in aging women |
| Q84566625 | Melatonin supplementation in rat ameliorates ovariectomy-induced oxidative stress |
| Q51363689 | Melatonin supplementation therapy as a potent alternative to ERT in ovariectomized rats. |
| Q39865023 | Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells. |
| Q50928841 | Memory symptoms during the menopausal transition. |
| Q34303751 | Meningioma and hormonal influences |
| Q39505249 | Menopausal age, related factors and climacteric symptoms in Libyan women |
| Q57288160 | Menopausal hormone therapy and breast cancer: what is the evidence from randomized trials? |
| Q95559379 | Menopausal hormone therapy and prevention of chronic diseases: IMS members react to the recent JAMA paper |
| Q46445810 | Menopausal hormone therapy and risk of hypertension. |
| Q38626233 | Menopausal hormone therapy for primary prevention: why the USPSTF is wrong |
| Q55868506 | Menopausal hormone therapy: a better and safer future |
| Q37919098 | Menopausal hot flushes and night sweats: where are we now? |
| Q37342902 | Menopausal hot flushes revisited |
| Q43929569 | Menopausal knowledge and perception in the Bulgarian population |
| Q34479995 | Menopausal obesity--myth or fact? |
| Q43858397 | Menopausal symptom control and side-effects on continuous estrone sulfate and three doses of medroxyprogesterone acetate. Ogen/Provera Study Group |
| Q79954334 | Menopausal symptoms and health problems of women aged 50-65 years in southern Jordan |
| Q48074446 | Menopausal symptoms and quality of life in Turkish women in the climacteric period |
| Q48792715 | Menopausal symptoms and risk factors for cardiovascular disease in postmenopause |
| Q50605141 | Menopausal symptoms and the metabolic syndrome in Nigerian women with type 2 diabetes mellitus. |
| Q47858752 | Menopausal symptoms appear before the menopause and persist 5 years beyond: a detailed analysis of a multinational study |
| Q91757624 | Menopausal symptoms are associated with non-adherence to highly active antiretroviral therapy in human immunodeficiency virus-infected middle-aged women |
| Q61786708 | Menopausal symptoms are associated with subclinical atherosclerosis in healthy recently postmenopausal women |
| Q51985302 | Menopausal symptoms in a hospital-based sample of women in southern Thailand. |
| Q48428591 | Menopausal symptoms in mid-life women in southern China |
| Q46905063 | Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. |
| Q35711777 | Menopausal symptoms within a Hispanic cohort: SWAN, the Study of Women's Health Across the Nation |
| Q92907669 | Menopausal symptoms, menopausal stage and cognitive functioning in black urban African women |
| Q39597449 | Menopausal symptoms: experience of Chinese women |
| Q43996439 | Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy |
| Q89505931 | Menopause - a new beginning |
| Q57587236 | Menopause Symptoms’ Severity Inventory (MSSI-38): assessing the frequency and intensity of symptoms |
| Q52957886 | Menopause World Congress in Berlin. |
| Q60712140 | Menopause alters the metabolism of serum serotonin precursors and their correlation with gonadotropins and estradiol |
| Q85624728 | Menopause and age-driven changes in blood level of fat- and water-soluble vitamins |
| Q36799434 | Menopause and aging, quality of life and sexuality. |
| Q36761433 | Menopause and cardiovascular disease: the evidence |
| Q84660606 | Menopause and hormone replacement. Introduction |
| Q48474522 | Menopause and post-polio symptoms as predictors of subjective sleep disturbance in poliomyelitis survivors |
| Q28221875 | Menopause and stroke and the effects of hormonal therapy |
| Q87398870 | Menopause and the workplace |
| Q47312801 | Menopause in Australia and Japan: effects of country of residence on menopausal status and menopausal symptoms |
| Q36645280 | Menopause in Egypt: past and present perspectives |
| Q47756699 | Menopause in the 21st century: the need for research and development |
| Q34428928 | Menopause is associated with lumbar disc degeneration: a review of 4230 intervertebral discs |
| Q46637951 | Menopause issues in Nigeria |
| Q37650406 | Menopause management: a cardiovascular risk-based approach |
| Q38133648 | Menopause or climacteric, just a semantic discussion or has it clinical implications? |
| Q83206688 | Menopause redefined |
| Q61842106 | Menopause redefined by the shift of paradigms |
| Q90675474 | Menopause research in Latin America |
| Q30239769 | Menopause, hormone therapy and diabetes |
| Q47722208 | Menopause, lung function and obstructive lung disease outcomes: a systematic review. |
| Q35605665 | Menopause, mood and management. |
| Q86530031 | Menopause--natural selection or modern disease? |
| Q48000453 | Menopause--quantifying the cost of symptoms |
| Q90334334 | Menopause-specific Quality of Life Questionnaire: factor and Rasch analytic approach |
| Q40185329 | Menopause-specific quality of life of a group of urban women, West Bengal, India |
| Q84159043 | Menopause: clustering of metabolic syndrome components and population changes in insulin resistance |
| Q81594627 | Menopause: why does fertility end before life? |
| Q51958764 | Mental health among perimenopausal women attending a menopause clinic: possible association with premenstrual syndrome? |
| Q92307928 | Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms |
| Q46025504 | Metabolic syndrome and its associated risk factors in Brazilian postmenopausal women. |
| Q40386384 | Metabolic syndrome and the risk of breast cancer among postmenopausal women in North-West China |
| Q91320090 | Metabolic syndrome during female midlife: what are the risks? |
| Q50075574 | Metabolic syndrome in menopause and associated factors: a meta-analysis |
| Q81242900 | Metabolic syndrome in postmenopausal women: higher prevalence in the Northeastern Region of Brazil than in other Latin American countries and the influence of obesity and socioeconomic factors |
| Q46905060 | Metabolic syndrome throughout the menopausal transition: influence of age and menopausal status. |
| Q44667403 | Metformin for overweight women at midlife: a double-blind, randomized, controlled trial. |
| Q53757264 | Metformin treatment and evolution of endometrial cancer. |
| Q39303005 | Micro-dose transdermal estradiol for relief of hot flushes in postmenopausal Asian women: a randomized controlled trial |
| Q77803061 | Microanatomy of the female reproductive organs in postmenopause by scanning electron microscopy |
| Q46765954 | Microbiotica in women |
| Q37995322 | Micronized progesterone and its impact on the endometrium and breast vs. progestogens |
| Q91199056 | Microsatellite variation of ESR1, ESR2, and AR in Serbian women with primary ovarian insufficiency |
| Q46968340 | Mid-Aged Health in Women from the Indian Subcontinent (MAHWIS): a further quantitative and qualitative investigation of experience of menopause in UK Asian women, compared to UK Caucasian women and women living in Delhi |
| Q82331250 | Mid-age health in women from the Indian subcontinent (MAHWIS): general health and the experience of menopause in women |
| Q37849771 | Mid-life smoking and cognition |
| Q39969616 | Midlife ADHD in women: any relevance to menopause? |
| Q90966203 | Midlife women's health consequences associated with polycystic ovary syndrome |
| Q77811521 | Migraine in a specialist menopause clinic |
| Q88009537 | Migraine, hormones and the menopausal transition |
| Q43084105 | Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. |
| Q77811563 | Misleading claims for dietary isoflavones |
| Q34496551 | Modeling hot flushes and quality of life in breast cancer survivors |
| Q39824048 | Moderate alcohol consumption contributes to women's well-being through the menopausal transition |
| Q83966566 | Moderate dosage estrogen-androgen therapy improves continuation rates in postmenopausal women: impact of the WHI reports |
| Q38374840 | Monurelle Biogel(®) vaginal gel in the treatment of vaginal dryness in postmenopausal women |
| Q85401768 | Mood, menopause and hysterectomy |
| Q33244231 | More data on hormone therapy and coronary artery disease: comments on recent publications from the WHI and Nurses' Study |
| Q46425362 | Mortality toll due to avoiding estrogen therapy in hysterectomized women: estimates for 2002 – 2011. |
| Q36519822 | MsFLASH participants' priorities for alleviating menopausal symptoms |
| Q57045102 | Multichannel electromyography for the assessment of pelvic floor muscle function |
| Q84485148 | Multivitamin use and the risk of myocardial infarction |
| Q90546993 | Muscle health in Hispanic women. REDLINC VIII |
| Q51294678 | Muscle mass and insulin sensitivity in postmenopausal women after 6-month exercise training. |
| Q40791346 | Musculoskeletal pain and the reproductive life stage in women: is there a relationship? |
| Q44304196 | Mutational analysis of the FST gene in Chinese women with idiopathic premature ovarian failure |
| Q89920600 | My aspirations for the IMS |
| Q81317148 | My dream |
| Q51435935 | NNT, number needed to treat: does it have any real value? |
| Q50222444 | Native tissue repair versus mesh repair in pelvic organ prolapse surgery |
| Q48175319 | Neurokinin 3 receptor antagonism - the magic bullet for hot flushes? |
| Q101151173 | Neurokinin 3 receptor antagonists - prime time? |
| Q48578668 | Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density |
| Q44018616 | New animal model for the study of postmenopausal coronary and cerebral artery function: the Watanabe heritable hyperlipidemic rabbit fed on a diet avoiding phytoestrogens |
| Q36946829 | New attitudes to sexuality in the menopause: clinical evaluation and diagnosis |
| Q30396979 | New evidence for cardiac benefit of postmenopausal hormone therapy. |
| Q47562888 | New guidelines--new hope? |
| Q36939490 | New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation |
| Q38616755 | New management options for osteoporosis with emphasis on SERMs |
| Q34691279 | New products and regimens (since 2003). |
| Q84660585 | New trends in hormone therapy |
| Q39102524 | Newly developed vaginal atrophy symptoms II and vaginal pH: a better correlation in vaginal atrophy? |
| Q53806635 | Night sweats: it may be hemochromatosis. |
| Q48600248 | Nightmares, cardiac symptoms and the menopause |
| Q50935037 | No differences in performance on test of working memory and executive functioning between healthy elderly postmenopausal women using or not using hormone therapy. |
| Q47745584 | No increased death toll for long-term menopausal hormone therapy |
| Q90268543 | No vaginal estrogen therapy arm in an RCT trial on genitourinary syndrome of menopause is a concern |
| Q45237514 | Nocturia in relation to body mass index, smoking and some other life-style factors in women |
| Q46646668 | Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment period |
| Q87272193 | Non-alcoholic fatty liver disease and its associated risk factors in Brazilian postmenopausal women |
| Q88781285 | Non-clinical studies of progesterone |
| Q37965541 | Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice |
| Q36946834 | Non-estrogenic approaches for the treatment of climacteric symptoms |
| Q38121155 | Non-hormonal management of vasomotor symptoms |
| Q38065195 | Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview |
| Q46025498 | Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. |
| Q47970360 | Nordic walking increases circulating VEGF more than traditional walking training in postmenopause. |
| Q37396755 | Norepinephrine activity, as measured by MHPG, is associated with menopausal hot flushes |
| Q79330248 | Not all placebos are equally pleasing |
| Q113093680 | Novel approaches to fertility restoration in women with premature ovarian insufficiency |
| Q49168066 | Number of women needed in a prospective trial to prove potential cardiovascular benefit of hormone replacement therapy |
| Q38104777 | Nutrition and health during mid-life: searching for solutions and meeting challenges for the aging population. |
| Q95800259 | Obesity and metabolic syndrome during the menopause transition in Serbian women |
| Q47558845 | Obesity during female midlife |
| Q90431643 | Obesity in midlife: lifestyle and dietary strategies |
| Q37622975 | Obesity, metabolic complications and the menopause: an opportunity for prevention |
| Q91993082 | Objective and subjective vasomotor symptom outcomes in the CBT-Meno randomized controlled trial |
| Q45950632 | Of conflicts, conspiracies, red herrings, and black swans. |
| Q94529789 | Office hysteroscopy in the management of women with postmenopausal bleeding |
| Q92143892 | Office hysteroscopy: back to the future! |
| Q87874188 | On aspirations |
| Q91353863 | On the human condition |
| Q34120300 | On the need to clarify and disseminate contemporary knowledge of hormone therapy initiated near menopause |
| Q77803109 | Once and twice a week transdermal estradiol delivery systems: clinical efficacy and plasma estrogen levels |
| Q38127837 | Oncology in midlife and beyond. |
| Q50791267 | One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. |
| Q45394890 | One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women |
| Q50548967 | Online education: should we take it seriously? |
| Q98153974 | Online survey of genital and urinary symptoms among Japanese women aged between 40 and 90 years |
| Q43225739 | Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results |
| Q58578036 | Optimizing quality of life in perimenopause: lessons from the East |
| Q90662380 | Optimizing quality of life through sex steroids by their effects on neurotransmitters |
| Q82158615 | Optimizing women's health: Adult Women's Health & Medicine |
| Q46606644 | Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model. |
| Q42596905 | Oral contraceptives, hormone therapy and cardiovascular risk |
| Q34265629 | Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review |
| Q37677579 | Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy |
| Q89121815 | Osteoporosis and vascular calcification in postmenopausal women: a cross-sectional study |
| Q36946813 | Osteoporosis guidelines |
| Q46990986 | Osteoporosis: non-hormonal treatment |
| Q39695112 | Osteoporosis: therapies now and in the future. |
| Q79807878 | Out, damn ovary, out--the case for and against bilateral oophorectomy for benign disease |
| Q77811740 | Out-patient hysteroscopy in asymptomatic postmenopausal women |
| Q57171751 | Ovarian aging: an ongoing prospective community-based cohort study in middle-aged Chinese women |
| Q47701928 | Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy - a nationwide study |
| Q44547445 | Ovarian conservation at the time of hysterectomy for benign disease: where is the pendulum now? |
| Q37971474 | Ovarian stem cells and aging. |
| Q96167683 | Ovarian tissue cryopreservation and transplantation prevents iatrogenic premature ovarian insufficiency: first 10 cases in China |
| Q91192683 | Ovarian tissue cryopreservation for patients with premature ovary insufficiency caused by cancer treatment: optimal protocol |
| Q47314545 | Overcoming cultural and religious discrimination - the ascent of the woman |
| Q90613346 | Overview of perimenopausal contraception |
| Q88021283 | Ovulation inhibition by estetrol in an in vivo model |
| Q92307681 | PGRMC1 can trigger estrogen-dependent proliferation of breast cancer cells: estradiol vs. equilin vs. ethinylestradiol |
| Q91993143 | Pain management during diagnostic office hysteroscopy in postmenopausal women: a randomized study |
| Q43055691 | Pain symptoms during the menopausal transition and early postmenopause |
| Q94601764 | Pandemics: learning from the past |
| Q40110530 | Parallel assessment of the impact of different hormone replacement therapies on breast density by radiologist- and computer-based analyses of mammograms |
| Q47547509 | Passive smoking is associated with lower age at menopause |
| Q77811748 | Patient acceptability of and tolerance to a placebo intravaginal ring in hysterectomized women: a pilot study |
| Q86703136 | Patient information leaflets: friend or foe? |
| Q53158654 | Patient selection bias may derive from the improper usage of diagnostic methods. |
| Q48508474 | Pedro Ramón Figueroa Casas, 1936-2008. |
| Q92277512 | Pelvic floor dysfunction in midlife women |
| Q91601580 | Pelvic floor function around the menopause and how to improve it |
| Q57135701 | Pelvic floor muscle function and EMG in nulliparous women of different ages: a cross-sectional study |
| Q89914404 | Pelvic floor muscle training: mechanisms of action for the improvement of genitourinary syndrome of menopause |
| Q85362902 | Perimenopausal hormonal contraception--can we do better? |
| Q40705476 | Perimenopausal women in estrogen vasomotor trials: contribution to placebo effect and efficacy outcome |
| Q44909740 | Perimenopause and incidence of depression in midlife women: a population-based study in Taiwan |
| Q43893954 | Perimenstrual symptoms and symptoms at midlife in Puebla, Mexico |
| Q37778394 | Periodontitis and osteoporosis: a systematic review. |
| Q48054526 | Periodontitis impacts quality of life in postmenopausal women |
| Q40375149 | Persistency with estrogen replacement therapy among hysterectomized women after the Women's Health Initiative study. |
| Q46147497 | Persistent denial of undeniable bias |
| Q40511078 | Personal opinion: Treatment of vulvovaginal atrophy--are hidden interests and misinformation preventing better management? |
| Q48251223 | Personal view: Hormones and depression in women |
| Q38121154 | Pharmacogenomics and sexuality: a vision |
| Q64989014 | Pharmacokinetic comparison between Conpremin (Premarin) and a generic preparation of conjugated estrogens. |
| Q36762596 | Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule |
| Q51554660 | Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women. |
| Q42166363 | Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women |
| Q89427503 | Pharmacokinetics of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women |
| Q94587948 | Pharmacological and non-pharmacological pain relief for office hysteroscopy: an up-to-date review |
| Q33384192 | Pharmacology and clinical applications of selective estrogen receptor modulators |
| Q36276322 | Pharmacology of different progestogens: the special case of drospirenone |
| Q35605660 | Pharmacology of estradiol valerate/dienogest. |
| Q28268346 | Pharmacology of estrogens and progestogens: influence of different routes of administration |
| Q34672058 | Pheromones, sexual attractiveness and quality of life in menopausal women |
| Q56796311 | Phototherapy during treadmill training improves quadriceps performance in postmenopausal women |
| Q48729715 | Physical activity and age at menopause: the Nord-Trøndelag population-based health study |
| Q45008361 | Physical activity and cardiovascular risk factors at menopause: the Nord-Trøndelag health study |
| Q82512967 | Physical function in overweight postmenopausal women |
| Q101566332 | Physiologic and psychosocial changes of the menopause transition in US Latinas: a narrative review |
| Q77803119 | Phytoestrogen study design |
| Q77803088 | Phytoestrogens and the menopause |
| Q39050499 | Phytoestrogens induce apoptosis through a mitochondria/caspase pathway in human breast cancer cells |
| Q38979700 | Phytoestrogens induce differential effects on both normal and malignant human breast cells in vitro |
| Q46412159 | Phytoestrogens possess a weak antioxidant activity on low density lipoprotein in contrast to the flavonoid quercetin in vitro in postmenopausal women |
| Q77803085 | Phytoestrogens: dietary intake and excretion in postmenopausal Chinese women |
| Q80204455 | Placebo, deceit and complementary/alternative medicine |
| Q44018612 | Placebo-controlled trial of transdermal estrogen therapy alone in postmenopausal women: effects on arterial compliance and endothelial function |
| Q44624253 | Plasma leptin in postmenopausal women with coronary artery disease: effect of transdermal 17β-estradiol and intermittent medroxyprogesterone acetate |
| Q39695050 | Plasma nitrite/nitrate levels in women with postmenopausal hot flushes. |
| Q84885005 | Plausible--yes. But ... |
| Q34576639 | Points to consider for the development of new indications for hormone replacement therapies and estrogen-like molecules. Department of Urogynaecology, King's College Hospital, London |
| Q38124922 | Polycystic ovaries - beyond menopause |
| Q34575203 | Polycystic ovary syndrome and implications for the menopause. |
| Q38654905 | Polycystic ovary syndrome and metabolic syndrome: the worrisome twosome? |
| Q39432542 | Polymorphisms in VDR gene in Tunisian postmenopausal women are associated with osteopenia phenotype |
| Q51295281 | Polymorphisms in period genes and bone response to hormone therapy in postmenopausal Korean women. |
| Q57599560 | Pompei and Ferreira |
| Q92484147 | Population education of menopausal knowledge in China |
| Q38270597 | Positive well-being during the menopausal transition: a systematic review |
| Q38113819 | Possible role of PGRMC1 in breast cancer development |
| Q88218220 | Post NICE Guidelines: could precision prescribing of estrogen be achieved? |
| Q38013806 | Post-myocardial infarction hormone therapy revisited |
| Q86197567 | Post-oophorectomy estrogen use and breast cancer risk |
| Q90956237 | Postmenopausal androgen-secreting ovarian tumors: challenging differential diagnosis in two cases |
| Q34573306 | Postmenopausal bone remodelling and hormone replacement |
| Q86409648 | Postmenopausal cell and tissue sex-hormone metabolism: mechanisms of intracrinology |
| Q48834188 | Postmenopausal depression and dementia: are the 2D’s connected? |
| Q85414698 | Postmenopausal endometriosis--a new dimension |
| Q57130025 | Postmenopausal endometriosis: drawing a clearer clinical picture |
| Q77811543 | Postmenopausal estrogen-progestin therapy and breast cancer: a clinical response to epidemiological reports |
| Q37995321 | Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone |
| Q77430591 | Postmenopausal hormone replacement therapy use and risk of endometrial cancer in Japanese women |
| Q95621426 | Postmenopausal hormone therapy and blood pressure revisited |
| Q51861170 | Postmenopausal hormone therapy and cognition: effects of timing and treatment type. |
| Q95807465 | Postmenopausal hormone therapy and coronary artery atherosclerosis |
| Q37800495 | Postmenopausal hormone therapy and lung cancer |
| Q37223479 | Postmenopausal hormone therapy and the risk of venous thromboembolism |
| Q45786935 | Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women |
| Q28221869 | Postmenopausal hormones and coronary artery disease: potential benefits and risks |
| Q46646660 | Postmenopausal osteoporosis: therapeutic options |
| Q93182731 | Postoperative cognitive dysfunction in premenopausal versus postmenopausal women |
| Q35689928 | Potassium: more beneficial effects. |
| Q46470161 | Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients |
| Q73341224 | Potential risks of phytoestrogens: experience from animal models |
| Q37196407 | Potential role of progestogens in the control of adipose tissue and salt sensitivity via interaction with the mineralocorticoid receptor |
| Q35924756 | Practical recommendations for hormone replacement therapy in the peri- and postmenopause |
| Q87434530 | Predicting menopausal age with anti-Müllerian hormone: a cross-validation study of two existing models |
| Q47589220 | Prediction of age at menopause in women with polycystic ovary syndrome. |
| Q87918750 | Prediction of age at menopause in women with polycystic ovary syndrome: methodological issues |
| Q50550753 | Predictive value of stabilometry and fear of falling on falls in postmenopausal women. |
| Q51771971 | Predictors for metabolic syndrome in perimenopausal and postmenopausal Thai women. |
| Q43553770 | Predictors of intentions to use hormone replacement therapy in clinical postmenopausal women |
| Q47345402 | Predictors of malignancy in endometrial polyps: study of 421 women with postmenopausal bleeding. |
| Q85894374 | Predictors of postmenopausal dyspareunia |
| Q43506435 | Predictors of quality of life in peri- and postmenopausal Polish women living in Lublin Voivodeship |
| Q47300014 | Pregnancy history, coronary artery calcification and bone mineral density in menopausal women |
| Q37610376 | Premature menopause increases cardiovascular risk |
| Q50614574 | Premature menopause: a comprehensive understanding of psychosocial aspects. |
| Q38271744 | Premature ovarian failure with 46,XX,t(1;4)(p34.1;q34): first case report and literature review. |
| Q48696135 | Premature ovarian failure with FMR1 premutation, X chromosome mosaicism and blood lymphocyte microchimerism |
| Q44806091 | Premature ovarian failure: a growing concern |
| Q33278956 | Premature ovarian failure: a review |
| Q99208709 | Premature ovarian insufficiency: an International Menopause Society White Paper |
| Q38171557 | Premature ovarian insufficiency: how to improve reproductive outcome? |
| Q84520967 | Premature ovarian insufficiency: working towards an international database |
| Q37773989 | Premature surgical menopause and Factor V Leiden heterozygosity: case report and literature review |
| Q39296008 | Prescription pattern of traditional Chinese medicine for climacteric women in Taiwan. |
| Q81242866 | Press statement. Breast cancer and hormone therapy: a looking-glass mirror? |
| Q37264389 | Prevalence and determinants of fecal incontinence in premenopausal women in an Arabian community |
| Q33738275 | Prevalence and predictors of complementary and alternative medicine/non-pharmacological interventions use for menopausal symptoms within the UK Collaborative Trial of Ovarian Cancer Screening |
| Q45343864 | Prevalence and predictors of metabolic syndrome among Congolese pre- and postmenopausal women |
| Q38061200 | Prevalence of CAM use by UK climacteric women: a systematic review of surveys |
| Q39413967 | Prevalence of and satisfaction with complementary therapies and hormone replacement therapy in a specialist menopause clinic |
| Q43643134 | Prevalence of depression among postmenopausal women and related characteristics |
| Q36814906 | Prevalence of hot flushes and night sweats around the world: a systematic review |
| Q46709510 | Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer |
| Q38224583 | Prevalence of menopausal symptoms in Asian midlife women: a systematic review. |
| Q38163571 | Prevalence of menopausal symptoms in Australian women at midlife: a systematic review |
| Q43572605 | Prevalence of metabolic syndrome in pre- and postmenopausal Iranian women |
| Q41620605 | Prevalence of urinary incontinence according to hysterectomy status in the WHI observational study |
| Q38223587 | Prevention of diseases after menopause. |
| Q81049563 | Prevention of osteoporosis is still a valid aim for hormone therapy |
| Q88106090 | Prevention of postmenopausal osteoporosis in Chinese women: a 5-year, double-blind, randomized, parallel placebo-controlled study |
| Q46606640 | Preventive effect of oral estetrol in a menopausal hot flush model |
| Q89569068 | Preventive effects of Polygonum orientale L. on ovariectomy-induced osteoporosis in rats |
| Q95607820 | Preventive medicine: GYNs or GPs? |
| Q39269725 | Primary ovarian insufficiency with t(5;13): a case report and literature review on disrupted genes |
| Q38399459 | Primary prevention of cardiovascular disease with hormone replacement therapy |
| Q95412465 | Primary prevention of stroke in women |
| Q78481755 | Primum non nocere |
| Q89929556 | Prior endogenous and exogenous estrogen and incident dementia in the 10th decade of life: The 90+ Study |
| Q34575167 | Problems of endometrial histology interpretation |
| Q82413505 | Proceedings of an International Menopause Society Workshop. Pisa, Italy |
| Q81049578 | Profile of menopausal women in rural north India |
| Q89505934 | Progesterone |
| Q37995324 | Progesterone and bone: a closer link than previously realized |
| Q88935717 | Progesterone and human cognition |
| Q38104422 | Progesterone and related progestins: potential new health benefits |
| Q44624249 | Progesterone creams: do they work? |
| Q89372133 | Progesterone for the prevention and treatment of osteoporosis in women |
| Q89372087 | Progesterone for treatment of symptomatic menopausal women |
| Q45909582 | Progesterone increases resistance of ophthalmic and central retinal arteries in climacteric women. |
| Q85414674 | Progesterone to treat vasomotor symptoms |
| Q57487487 | Progesterone, progestins and the breast in menopause treatment |
| Q88187191 | Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy |
| Q34323606 | Progesterone--promoter or inhibitor of breast cancer |
| Q46039879 | Progestin may modify the effect of low-dose hormone therapy on mammographic breast density. |
| Q44793608 | Progestins initiate adverse events of menopausal estrogen therapy |
| Q38327714 | Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells |
| Q88131317 | Progestogens and pregnancy loss |
| Q60650751 | Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis |
| Q54429618 | Progestogens reduce thromboxane production by cultured human endothelial cells. |
| Q50796047 | Prognostic role of heart rate in patients referred for coronary angiography: age and sex differences. |
| Q82439619 | Prothrombotic mutations, family history and the risk of thrombosis in postmenopausal women: implications for hormone replacement therapy |
| Q47907168 | Psychological but not vasomotor symptoms are associated with temperament and character traits |
| Q91955389 | Psychological issues in cancer survivorship |
| Q44132555 | Psychological well-being and mental health among users and non-users of hormone therapy |
| Q58101908 | Psychometric evaluation of electronic diaries assessing side-effects of hormone therapy |
| Q57590477 | Psychometric properties of a scale to measure menopause-related symptoms in two ethnicities |
| Q38904597 | Psychometric properties of the Tunisian-Arabic version of the Women's Health Questionnaire |
| Q44670804 | Psychosocial adjustment in women with premature menopause: a cross-sectional survey |
| Q48666281 | Psychosocial factors, attitude to menopause and symptoms in Swedish perimenopausal women |
| Q46196665 | Psychosocial work environment and lifestyle as related to lipid profiles in perimenopausal women |
| Q55040705 | Published results on breast cancer and hormone replacement therapy in the Million Women Study are correct. |
| Q92519566 | Publishing in Climacteric |
| Q52968884 | Publishing the results of the estrogen-only arm of WHI. |
| Q77811559 | Pulsatile release of sex steroids? A hypothesis to explain anomalies in hormonal therapy |
| Q35025796 | Pulsed estrogen therapy: from cellular mode of action to tissue effects |
| Q35025802 | Pulsed estrogen therapy: relieving climacteric symptoms, preventing postmenopausal bone loss. |
| Q31069504 | Purified phytoestrogens in postmenopausal bone health: is there a role for genistein? |
| Q48500970 | Quality of life and climacteric complaints amongst women seeking medical advice in Taiwan: assessment using the WHOQOL-BREF questionnaire |
| Q43841485 | Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy |
| Q37610390 | Quality of life and sexuality issues in aging women |
| Q38011780 | Quality of life and the role of menopausal hormone therapy |
| Q57053735 | Quality of life for women with endometriosis: premenopausal and postmenopausal perspectives |
| Q47585633 | Quality of life in climacteric women |
| Q53409270 | Quality of life of breast cancer survivors: the impact of hormonal replacement therapy. |
| Q46646672 | Quality-of-life assessment in community-dwelling, middle-aged, healthy women in Japan |
| Q79330256 | Quantitative ultrasonometry of the phalanges during pregnancy: a longitudinal study |
| Q42448862 | RETRACTED: Bone mineral density of lumbar spine and femur in patients with gynecologic cancer |
| Q51192195 | RETRACTED: Different bone mineral density in cervical and endometrial cancer. |
| Q44018603 | Raloxifene and cardiovascular disease |
| Q30838964 | Raloxifene, soy phytoestrogens and endothelial function in postmenopausal women |
| Q39188428 | Randomized clinical trial of a handheld cooling device (Menopod®) for relief of menopausal vasomotor symptoms. |
| Q82424644 | Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms |
| Q77811777 | Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women |
| Q45237519 | Randomized trial of effects of estradiol in combination with either norethisterone acetate or trimegestone on lipids and lipoproteins in postmenopausal women |
| Q129631697 | Randomized trial: treatment of genitourinary syndrome of menopause using radiofrequency |
| Q91195814 | Rationale and design for fractional microablative CO2 laser versus photothermal non-ablative erbium:YAG laser for the management of genitourinary syndrome of menopause: a non-inferiority, single-blind randomized controlled trial |
| Q35772337 | Rationale and design for the Vaginal Erbium Laser Academy Study (VELAS): an international multicenter observational study on genitourinary syndrome of menopause and stress urinary incontinence |
| Q79807882 | Re-think HRT: behind the scene of perceptions |
| Q36946779 | Recent epidemiological evidence relevant to the clinical management of the menopause |
| Q52892858 | Recommendation for the collection and analysis of endometrial biopsies for hormone therapies. |
| Q39495007 | Recommendations for the management of postmenopausal vaginal atrophy |
| Q36799444 | Recommendations from a multi-study evaluation of proposed criteria for staging reproductive aging. |
| Q91574274 | Recurrent disease after treatment for cervical pre-cancer: determining whether prophylactic HPV vaccination could play a role in prevention of secondary lesions |
| Q95780544 | Recurrent venous thromboembolism in estrogen users |
| Q91824689 | Reducing mid-life cardiovascular disease by improving reproductive health |
| Q79954315 | Reducing the problems of the progestogen |
| Q39292662 | Reduction of serum serotonin precursors after veralipride treatment for postmenopausal hot flushes |
| Q103737580 | Reflecting back and looking forward |
| Q34575210 | Regulation of endometrial angiogenesis |
| Q46378679 | Relation between body mass index and endothelium-dependent vasodilatation in healthy postmenopausal women |
| Q50598820 | Relation between oxidative stress and climacteric symptoms in early postmenopausal women. |
| Q79963169 | Relation of body mass and sex steroid hormone levels to hot flushes in a sample of mid-life women |
| Q44426074 | Relationship between climacteric symptoms and serum serotonin levels in postmenopausal women |
| Q53314249 | Relationship between decreased bone mineral density and subclinical atherosclerosis in postmenopausal women. |
| Q38821098 | Relationship between delivery modes and genitourinary syndrome among postmenopausal women. |
| Q44322731 | Relationship between different protein intake recommendations with muscle mass and muscle strength |
| Q77803076 | Relationship between menopausal stage and age and quality of relationships with partners, children and friends |
| Q51367708 | Relationship between reproductive aging, body composition, hormonal status and metabolic syndrome in postmenopausal women. |
| Q91791465 | Relationship between serum homocysteine and different menopausal stage |
| Q51248110 | Relationship between serum uric acid levels and hepatic steatosis in non-obese postmenopausal women. |
| Q50879647 | Relationship between serum uric acid levels and metabolic syndrome in Chinese postmenopausal women. |
| Q43191179 | Relationship between the percentage of predicted cardiorespiratory fitness and cardiovascular disease risk factors in premenopausal women: a MONET study |
| Q100996361 | Relationship between vasomotor symptoms and metabolic syndrome in Chinese middle-aged women |
| Q48482341 | Relationship between women's attitude towards menopause and quality of life |
| Q47626110 | Relationships between 25(OH)D concentration, sarcopenia and HOMA-IR in postmenopausal Korean women |
| Q90377370 | Relationships between depression and food intake in climacteric women |
| Q34294335 | Relaxin: a possible future preventive therapy for cardiovascular disease in postmenopausal women and men? |
| Q81604223 | Relevance of the results of the Women's Health Initiative on the prescription of hormone therapy in Spain |
| Q50916380 | Reliable evidence from placebo-controlled, randomized, clinical trials for menopausal hormone therapy's influence on incidence and deaths from breast cancer. |
| Q84080745 | Relief of vaginal discomfort - hormones or water? |
| Q52954621 | Report on the 10th World Congress on the Menopause. 10-14 June 2002, Berlin, Germany. |
| Q51922699 | Reproductive period and cognitive function in a representative sample of naturally postmenopausal women aged 60-64 years. |
| Q39277783 | Resilience and related factors in urban, mid-aged Spanish women. |
| Q48424198 | Restless legs syndrome among women: prevalence, co-morbidity and possible relationship to menopause. |
| Q87188140 | Retraction Statement |
| Q87604887 | Retraction Statement |
| Q30681796 | Retrospective self-report compared with menstrual diary data prospectively kept during the menopausal transition |
| Q100455909 | Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms - an update on the evidence |
| Q35684567 | Review of alternative therapies for treatment of menopausal symptoms |
| Q92896320 | Reviewing the evidence on vasomotor symptoms: the role of traditional and non-traditional factors |
| Q53759974 | Revised Global Consensus Statement on Menopausal Hormone Therapy. |
| Q90710510 | Ringing the bell and then falling off a cliff … life after cancer |
| Q46877651 | Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. |
| Q79136496 | Risk communication in consultations about hormone therapy in the menopause: concordance in risk assessment and framing due to the context |
| Q54546191 | Risk factors for HR- and HER2-defined breast cancer in Slovenian postmenopausal women. |
| Q46883343 | Risk factors for type 2 diabetes in women attending menopause clinics in Italy: a cross-sectional study |
| Q91295711 | Risk factors of long-term mortality in middle-aged women: a 27-year follow-up cohort |
| Q53810075 | Risk of breast cancer among users of estrogen plus progestogen and unopposed estrogen: is the likelihood of bias symmetrical? |
| Q46916582 | Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: detection bias and resolution of discrepant findings in two Women's Health Initiative studies |
| Q45946884 | Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations. |
| Q43244412 | Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations |
| Q35012367 | Risk of hypoactive sexual desire disorder and associated factors in a cohort of oophorectomized women |
| Q44927904 | Risks and benefits of hormone therapy: has medical dogma now been overturned? |
| Q44789962 | Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial |
| Q86569046 | Role of biochemical markers in the management of osteoporosis |
| Q49982066 | Role of breast density measurement in screening for breast cancer |
| Q88766983 | Role of melatonin in circadian rhythm at menopause |
| Q36019567 | Role of progestins with partial antiandrogenic effects |
| Q49956708 | Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial. |
| Q50102654 | Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials |
| Q95780552 | Routine calcium and vitamin D supplementation: the end of the story? |
| Q57288157 | Royal jelly does not prevent bone loss but improves bone strength in ovariectomized rats |
| Q91685894 | SCD1 methylation in subcutaneous adipose tissue associated with menopausal age |
| Q86788187 | SERMs, vulvovaginal atrophy and breast cancer |
| Q44982985 | Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis |
| Q35025804 | Safety and tolerability of pulsed estrogen therapy: key factors for an improved compliance. |
| Q36761448 | Safety of alternative treatments for menopausal symptoms after breast cancer: a qualitative systematic review |
| Q92577325 | Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines |
| Q95412470 | Safety of low-dose paroxetine |
| Q101124517 | Safety of vaginal erbium laser: A review of 113,000 patients treated in the past 8 years |
| Q48369052 | Salivary α-amylase and cortisol after exercise in menopause: influence of long-term HRT. |
| Q50954819 | Sarcoidosis of the vagina treated with methotrexate. |
| Q87339184 | Satiety quotient linked to food intake and changes in anthropometry during menopause: a MONET Study |
| Q47670520 | Screening for general anxiety disorders in postmenopausal women with symptomatic pelvic organ prolapse |
| Q88528711 | Screening for women at midlife: we need to remain vigilant |
| Q30851278 | Screening mammography--early detection or over-diagnosis? Contribution from Australian data |
| Q92907692 | Screening sarcopenia through SARC-F in postmenopausal women: a single-center study from South America |
| Q95820987 | Second thoughts on the women's health initiative study: the effect of age on the safety of HRT |
| Q87105771 | Sedentary women: sit less, live more! |
| Q84080740 | Seismic shifts |
| Q86915832 | Selection criteria for patients with non-alcoholic fatty liver disease and diabetes mellitus to achieve reliable results |
| Q77803024 | Selective estrogen receptor modulators |
| Q36799439 | Selective estrogen receptor modulators and risk for coronary heart disease. |
| Q34575198 | Selective estrogen receptor modulators: tissue selectivity and differential uterine effects |
| Q47729672 | Selective progesterone receptor modulators: current applications and perspectives. |
| Q39861591 | Self-care actions taken for vasomotor symptoms by some postmenopausal Kelantanese women |
| Q92310204 | Self-regulation model applied to menopause: a mixed-methods study |
| Q59543961 | Self-reported arthritis and the menopause |
| Q51186823 | Sequential treatment with monofluorophosphate and zoledronic acid in osteoporotic rats. |
| Q48018117 | Serbian version of the Women's Health Questionnaire: psychometric properties |
| Q84811036 | Sertraline improves the somatic and psychological symptoms of the climacteric syndrome |
| Q46877655 | Serum C-reactive protein and plasma homocysteine levels are associated with hormone therapy use and other factors: a population-based study of middle-aged Australian-born women |
| Q50983930 | Serum and saliva magnesium in postmenopausal women with xerostomia. |
| Q52122279 | Serum estrogen level, attention, memory and other cognitive functions in middle-aged women. |
| Q48083275 | Severe PMS/PMDD - is it time for a new approach? |
| Q48368810 | Severe menopausal symptoms in mid-aged Latin American women can be related to their indigenous ethnic component |
| Q92141064 | Severity of hot flushes is inversely associated with dietary intake of vitamin B6 and oily fish |
| Q47294037 | Severity of menopausal symptoms and cardiovascular and osteoporosis risk factors |
| Q46824145 | Severity of menopausal symptoms of Jordanian women |
| Q48678905 | Sex hormones and cerebral hemodynamics |
| Q36892319 | Sex steroids and cutaneous wound healing: the contrasting influences of estrogens and androgens. |
| Q38416122 | Sex, stress and the brain: interactive actions of hormones on the developing and adult brain |
| Q48070729 | Sexual activity and functioning in ovarian cancer survivors: an internet-based evaluation. |
| Q90675485 | Sexual dysfunction in perimenopausal women based on a national epidemiological survey in China |
| Q92032649 | Sexual function after cancer: paying the price of survivorship |
| Q35353723 | Sexual function after fractional microablative CO₂ laser in women with vulvovaginal atrophy |
| Q101124508 | Sexual function after vaginal erbium laser: the results of a large, multicentric, prospective study |
| Q91939969 | Sexual function through decades: association with androgens and cardiometabolic features |
| Q46446770 | Sexual function, mood and menopause symptoms in Lithuanian postmenopausal women |
| Q38989634 | Sexual health in Spanish postmenopausal women presenting at outpatient clinics |
| Q58087267 | Sexual quality of life in men and women after cancer |
| Q28293237 | Sexual steroids in urogynecology |
| Q56342088 | Sexual well-being after menopause: An International Menopause Society White Paper |
| Q44789965 | Sexuality in healthy postmenopausal women |
| Q92547672 | Sexuality in premature ovarian insufficiency |
| Q38011785 | Shock, terror and controversy: how the media reacted to the Women's Health Initiative |
| Q89092814 | Short-term tibolone does not interfere with endothelial function: a double-blinded, randomized, controlled trial |
| Q43495287 | Should epidemiology, the media and quangos determine clinical practice? |
| Q48072004 | Should menopausal characteristics be considered during cardiorespiratory exercise prescription in postmenopausal women? |
| Q50917694 | Should we abstain from treating women with endometriosis using menopausal hormone therapy, for fear of an increased ovarian cancer risk? |
| Q95763720 | Should we be satisfied with the available anti-fracture therapies? |
| Q51737697 | Should we consider assessment of bone mineral density earlier in postmenopausal women with pelvic organ prolapse? |
| Q38609024 | Should we prescribe calcium or vitamin D supplements to treat or prevent osteoporosis? |
| Q49976217 | Should women be screened for osteoporosis at midlife? |
| Q77811734 | Significant differences in estradiol bioavailability from two similarly labelled estradiol matrix transdermal systems |
| Q47784145 | Similarity of female central (hypogonadotropic) hypogonadism and postmenopause |
| Q113390615 | Skin, hair and beyond: the impact of menopause |
| Q38064492 | Sleep and sleep disorders in menopausal women |
| Q47897717 | Sleep difficulty mediates effects of vasomotor symptoms on mood in younger breast cancer survivors. |
| Q47595772 | Sleep disturbance, obesity, physical fitness and quality of life in older women: EXERNET study group. |
| Q44981199 | Sleep disturbances, oxidative stress and cardiovascular risk parameters in postmenopausal women complaining of insomnia. |
| Q39373329 | Sleep duration and midlife women's health |
| Q44689222 | Sleep, vigilance and cognition in postmenopausal women: placebo-controlled studies with 2 mg estradiol valerate, with and without 3 mg dienogest. |
| Q46412156 | Smoking reduces breast tenderness during oral estrogen-progestogen therapy |
| Q46167010 | Social media and health |
| Q77811482 | Sociodemographic and clinical factors associated with HRT use in women attending menopause clinics in Italy |
| Q46259275 | Sociodemographic risk factors of metabolic syndrome in middle-aged women: results from a population-based study of Swedish women, The Women's Health in the Lund Area (WHILA) Study |
| Q44789976 | Some comments on the Million Women Study |
| Q35606928 | Soy and red clover for mid-life and aging |
| Q95802108 | Soy for bone protection and vasomotor symptoms |
| Q44109296 | Soy isoflavones and exercise to improve physical capacity in postmenopausal women |
| Q48513307 | Soy isoflavones improve insulin sensitivity without changing serum leptin among postmenopausal women |
| Q46978899 | Soybean concentrated extract counteracts oxidative stress in the uterus of rats |
| Q44798016 | Soybean isoflavones attenuate the expression of genes related to endometrial cancer risk. |
| Q82131884 | Spotlight on severe premenstrual syndrome and bipolar disorder: a frequent tragic confusion |
| Q92614945 | Spouses' perceptions of and attitudes toward female menopause: a mixed-methods systematic review |
| Q84803362 | Statins in women for primary prevention--is there evidence to back up their use?? |
| Q42669914 | Stellate-ganglion block as a treatment for severe postmenopausal flushing |
| Q83394779 | Stopping HRT: were women ill advised? |
| Q84778518 | Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis |
| Q50740143 | Studying the menopausal transition: methodological considerations. |
| Q51890729 | Subjective cognitive complaints at menopause associated with declines in performance of verbal memory and attentional processes. |
| Q39769189 | Subjective insomnia is associated with low sleep efficiency and fatigue in middle-aged women. |
| Q46236710 | Substituting food restriction by resistance training prevents liver and body fat regain in ovariectomized rats |
| Q43424580 | Sugary foods and gynecological cancer risk |
| Q41100869 | Sulfur dioxide exposure and other factors affecting age at natural menopause in the Jinchuan cohort |
| Q87918591 | Surgical challenges in the treatment of perimenopausal and postmenopausal endometriosis |
| Q90675537 | Surgical management of pelvic organ prolapse |
| Q38185755 | Surgical menopause and cognitive decline |
| Q48082724 | Surgical prevention of epithelial ovary cancer without oophorectomy: changing the future. |
| Q39909184 | Symptoms at menopause and care of grandchildren. |
| Q31164239 | Symptoms in peri- and postmenopausal women in relation to testosterone concentrations: data from The Women's Health in the Lund Area (WHILA) study |
| Q48112451 | Symptoms, health behavior and understanding of menopause therapy in women with premature menopause. |
| Q89427514 | Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy |
| Q38126067 | Systematic review about breast cancer incidence in relation to hormone replacement therapy use. |
| Q83931035 | Systemic effects of conjugated equine estrogen vaginal cream on bone turnover markers in postmenopausal women |
| Q90966214 | Systemic lupus erythematosus and menopause |
| Q47683791 | TBP2 gene may not be associated with primary ovarian insufficiency |
| Q92307159 | TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women |
| Q92228251 | Tailored hormonal approach in women with premature ovarian insufficiency |
| Q48792891 | Taking an integrated approach: managing women with phytoestrogens |
| Q43971615 | Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study |
| Q89835202 | Teaching the teachers |
| Q43702448 | Telomere length and telomerase activity in the context of menopause |
| Q44355123 | Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women |
| Q83449808 | Ten-year fracture risk in the assessment of osteoporosis management efficacy in postmenopausal women: a pilot study |
| Q48580244 | Testosterone addition during menopausal hormone therapy: effects on mammographic breast density |
| Q38059219 | Testosterone concentrations in ovarian insufficiency: a review. |
| Q36226990 | Testosterone in older men after the Institute of Medicine Report: where do we go from here? |
| Q37196403 | Testosterone therapy for sexual dysfunction in postmenopausal women |
| Q43157784 | Testosterone treatment of HSDD in naturally menopausal women: the ADORE study |
| Q97684670 | Testosterone use in postmenopausal women |
| Q55041557 | The 'bioidentical/bioequivalent' hormone scam. |
| Q87874187 | The 'window of opportunity'--should we be taking it? |
| Q45951188 | The American-European difference in vulvar and vaginal atrophy views: a lesson from the REVIVE Survey. |
| Q61853019 | The CROWN Initiative: journal editors invite researchers to develop core outcomes in women's health |
| Q64938624 | The ERA trial: findings and implications for the future. |
| Q51761819 | The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. |
| Q77811802 | The HERS trial |
| Q36892314 | The HRT misuse and osteoporosis epidemic: a possible future scenario |
| Q103737578 | The IMS: charting a course forward |
| Q77826416 | The International Menopause Society menopause-related terminology definitions |
| Q40060847 | The International Menopause Study of Climate, Altitude, Temperature (IMS-CAT) and vasomotor symptoms. |
| Q48666271 | The Menopause Rating Scale (MRS): comparison with Kupperman index and quality-of-life scale SF-36. |
| Q51958743 | The Menopause Rating Scale (MRS): reliability of scores of menopausal complaints. |
| Q57053728 | The Menopause Visual Analogue Scale: a new tool for measuring the severity and response to treatment of symptoms throughout the menopausal transition |
| Q46877631 | The Million Women Study--is it believable? |
| Q43805218 | The Million Women Study: potential biases do not allow uncritical acceptance of the data |
| Q38936484 | The NICE Guideline - Menopause: diagnosis and management |
| Q38665126 | The UK breast screening program - what you need to know |
| Q44522887 | The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women |
| Q101124507 | The VELA experience: a strategic format |
| Q43494898 | The WHI: have our worst fears come true? |
| Q34276283 | The WHI: the effect of hormone replacement therapy on fracture prevention |
| Q84183716 | The Women's Health Initiative - a decade of progress |
| Q42652062 | The acceptability of a small intrauterine progestogen-releasing system for continuous combined hormone therapy in early postmenopausal women |
| Q46877645 | The acceptability of isoflavones as a treatment of menopausal symptoms: a European survey among postmenopausal women |
| Q77430584 | The ascent of woman |
| Q30689510 | The assessment of bleeding patterns in postmenopausal women during continuous combined hormone replacement therapy: a review of methodology and recommendations for reporting of the data |
| Q48347945 | The assessment of efficacy of Diascorea alata for menopausal symptom treatment in Taiwanese women |
| Q38613153 | The association between hot flushes and smoking in midlife women: a meta-analysis |
| Q92483827 | The association between sexual dysfunction and metabolic syndrome among Turkish postmenopausal women |
| Q96581629 | The association between vitamin D receptor FokI gene polymorphism and osteoporosis in postmenopausal women: a meta-analysis |
| Q97562370 | The association of bisphenol A exposure with premature ovarian insufficiency: a case-control study |
| Q47935482 | The association of hyperuricemia and metabolic syndrome in Thai postmenopausal women |
| Q43764385 | The association of osteopenia with levels of serum 25-hydroxyvitamin D and HOMA-IR values |
| Q91955100 | The associations between menopausal symptoms and sleep quality in Spanish postmenopausal women |
| Q78004617 | The bleeding problem |
| Q38260474 | The cardiovascular safety aspects of calcium supplementations: where does the truth lie? A personal perspective |
| Q77803043 | The change to Climacteric |
| Q35626394 | The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy |
| Q41129195 | The clinical significance of endometrial fluid collection in asymptomatic postmenopausal women |
| Q95607811 | The contraceptive needs of the perimenopausal woman |
| Q77811473 | The descent of woman |
| Q61786753 | The differential effect of estrogen, estrogen–progestin and tibolone on coagulation inhibitors in postmenopausal women |
| Q48489655 | The dilemma of menopause and hormone replacement--a challenge for women and health-care providers: knowledge of menopause and hormone therapy in Spanish menopausal women |
| Q77811774 | The effect of Promensil, an isoflavone extract, on menopausal symptoms |
| Q55042068 | The effect of a 10-week Nordic walking training program on the level of GH and LH in elderly women. |
| Q46932039 | The effect of age and menopausal status on musculoskeletal symptoms in Chinese women aged 35-64 years |
| Q46259268 | The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors. |
| Q46528065 | The effect of estrogen plus progestin treatment on sleep: a randomized, placebo-controlled, double-blind trial in premenopausal and late postmenopausal women |
| Q48930844 | The effect of hysterectomy and/or oophorectomy on sexual satisfaction |
| Q79954330 | The effect of hysterectomy on ovarian blood supply and endocrine function |
| Q90165032 | The effect of menopausal symptoms on the quality of life among postmenopausal Egyptian women |
| Q36112290 | The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women |
| Q46877658 | The effect of postmenopausal hormone therapy with or without folic acid supplementation on serum homocysteine level |
| Q50140079 | The effect of programmed exercise over anxiety symptoms in midlife and older women: a meta-analysis of randomized controlled trials |
| Q91797077 | The effect of serotonin reuptake inhibitors on the vaginal epithelium in postmenopausal women |
| Q83142071 | The effect of soy isoflavone on bone mineral density |
| Q40616677 | The effect of surgical menopause on the intima-media thickness of the carotid and coronary arteries. |
| Q83303839 | The effect of total abdominal hysterectomy on serum anti-Müllerian hormone levels: a pilot study |
| Q90866058 | The effect of vitamin D2 supplementation on muscle strength in early postmenopausal women: a randomized, double-blind, placebo-controlled trial |
| Q83679667 | The effects of cinnarizine on menopausal symptoms in women |
| Q45348574 | The effects of conjugated estrogen, raloxifene and soy extract on collagen in rat bones |
| Q36258640 | The effects of dehydroepiandrosterone on sexual function: a systematic review |
| Q44982970 | The effects of dietary supplementation with isoflavones from red clover on cognitive function in postmenopausal women |
| Q37547019 | The effects of hormone replacement therapy on autoimmune disease: rheumatoid arthritis and systemic lupus erythematosus |
| Q43293543 | The effects of hormone replacement therapy on myocardial performance in early postmenopausal women |
| Q38483271 | The effects of hormone therapy on metabolic risk factors in postmenopausal Korean women |
| Q34605075 | The effects of hormones on urinary incontinence in postmenopausal women |
| Q51886406 | The effects of micronutrient supplementation on vasomotor symptoms in postmenopausal women. |
| Q104741328 | The effects of phytoestrogens on postmenopausal health |
| Q80287867 | The effects of short-term hormone replacement therapy on long-term bone mineral density |
| Q39408971 | The effects of soy protein containing phytoestrogens on menopausal symptoms in postmenopausal women |
| Q43622088 | The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women |
| Q43584229 | The efficacy and safety of bazedoxifene in postmenopausal women by baseline kidney function status |
| Q39378397 | The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review |
| Q34053682 | The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review |
| Q39653842 | The emergence of the menopause in India |
| Q73100085 | The end of WISDOM |
| Q37631061 | The endometrium--from estrogens alone to TSECs |
| Q35095008 | The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer |
| Q90958247 | The etiology and management of recurrent urinary tract infections in postmenopausal women |
| Q39158613 | The evidence base for HRT: what can we believe? |
| Q26827973 | The evolution of selective estrogen receptor modulators in osteoporosis therapy |
| Q91320083 | The evolution of the human menopause |
| Q61807517 | The existence and potential of germline stem cells in the adult mammalian ovary |
| Q53201151 | The experience of menopausal symptoms by Arabic women in Sydney. |
| Q91955371 | The first family group of α1-AT-P in the world with repeated hematomas: 10-year follow-up |
| Q100377761 | The first major complication due to laser treatment for stress urinary incontinence: a short report |
| Q77811767 | The four harms of harmless therapies |
| Q47582338 | The futile case of the aging ovary: is it mission impossible? A focused review |
| Q92093774 | The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis |
| Q80676794 | The heart of the WHI study: time for hormone therapy policies to be revised |
| Q101124505 | The heat is on |
| Q37610388 | The hemostatic system through aging and menopause. |
| Q64012535 | The history of natural progesterone, the never-ending story |
| Q47572880 | The hope for KEEPS. |
| Q47329401 | The hopeless age? A qualitative exploration of the experience of menopause in Arab women in Qatar. |
| Q88500162 | The hot flush: symptom of menopause or sign of disease? |
| Q53484275 | The hot flush: the enigma of the climacteric. |
| Q48001604 | The impact of a sexual enhancement program on the sexual function of postmenopausal women |
| Q96581892 | The impact of menopausal hormone therapy on overall mortality - a comprehensive review |
| Q48509759 | The impact of micronized progesterone on breast cancer risk: a systematic review |
| Q38859193 | The impact of micronized progesterone on the endometrium: a systematic review |
| Q46244173 | The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor-alpha and hepatocyte growth factor in postmenopausal women |
| Q95817463 | The importance of HT dose, formulation and route of delivery |
| Q34265657 | The importance of patient education in improving compliance |
| Q48126965 | The importance of quality of sleep in menopause |
| Q40341830 | The influence of body fat distribution patterns and body mass index on MENQOL in women living in an urban area |
| Q48368613 | The influence of physical activity level on climacteric symptoms in menopausal women |
| Q83336923 | The influence of premenopausal hormones on severity of climacteric symptoms and use of HRT |
| Q45556999 | The influence of smoking on bone loss and response to nasal estradiol. |
| Q46873735 | The influence of smoking on uterine bleeding during continuous and interrupted oral hormone therapy |
| Q80204484 | The influence of smoking on uterine bleeding during sequential oral hormone therapy |
| Q47949149 | The influence of unilateral oophorectomy on the age of menopause. |
| Q47995676 | The intensity of menopausal symptoms is associated with episodic memory in postmenopausal women |
| Q38305580 | The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review |
| Q34393279 | The life and times of the estrogen receptors: an interim report |
| Q53193367 | The long-term effect of raloxifene on the genitourinary tract. |
| Q79330253 | The long-term effects of low-dose 17beta-estradiol and dydrogesterone hormone replacement therapy on 24-h ambulatory blood pressure in hypertensive postmenopausal women: a 1-year randomized, prospective study |
| Q46877640 | The long-term effects of tibolone on aortic stiffness and endothelial function |
| Q83336913 | The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women |
| Q90710421 | The maintenance effect of acupuncture on breast cancer-related menopause symptoms: a systematic review |
| Q48956904 | The menopausal experience among indigenous women of Sarawak, Malaysia. |
| Q39221449 | The menopausal hot flush: a review |
| Q85441479 | The menopausal transition does not appear to accelerate age-related increases in arterial stiffness |
| Q44570145 | The menopausal transition: a 9-year prospective population-based study. The Melbourne Women's Midlife Health Project |
| Q50775123 | The menopausal transition: does it induce women's worries about aging? |
| Q38550074 | The menopause 'It's somewhere between a taboo and a joke'. A focus group study |
| Q77811501 | The menopause in Japan--Konenki Jigoku |
| Q53130386 | The menopause symptom profile of Maori and non-Maori women in New Zealand. |
| Q91574133 | The metabolic syndrome and diabetes are not synonymous |
| Q34265648 | The need for continuing education of the prescriber. |
| Q90675553 | The neurokinin B pathway in the treatment of menopausal hot flushes |
| Q54187145 | The new Climacteric. |
| Q37470341 | The new frontier of bone formation: a breakthrough in postmenopausal osteoporosis? |
| Q79184595 | The new terminology |
| Q53194815 | The pattern of lipids and lipoproteins during the menopausal transition in Chinese women. |
| Q83336904 | The pendulum swings back; estrogen is now beneficial if started at the right time |
| Q56786425 | The perception of menopause and hormone therapy among women in Turkey |
| Q53131292 | The pharma industry--redressing the balance. |
| Q88208293 | The platelet-to-lymphocyte ratio as a predictor of patient outcomes in ovarian cancer: a meta-analysis |
| Q81326963 | The position of the Regulatory Authorities |
| Q88593245 | The prevalence and determinants of genitourinary syndrome of menopause in Chinese mid-life women: a single-center study |
| Q40529523 | The prevalence of symptomatic pelvic floor disorders in women in Bangladesh |
| Q90675509 | The prevalence of urinary incontinence |
| Q39175749 | The quest for new drugs to prevent osteoporosis-related fractures |
| Q34265635 | The rationale for a wider range of progestogens |
| Q46136093 | The reality is that the number of women with menopausal symptoms wanting to consider alternative therapies rather than hormone replacement therapy (HRT) has increased over the last decade. Introduction |
| Q85221535 | The relationship between estrogen receptor gene polymorphism and mammographic density in postmenopausal women |
| Q33538268 | The relationship between psychosocial status, acculturation and country of origin in mid-life Hispanic women: data from the Study of Women's Health Across the Nation (SWAN). |
| Q44961483 | The relationship between urogenital symptoms and climacteric complaints |
| Q95821275 | The relationship of mammographic density and age |
| Q50875469 | The relationship of reports of aches and joint pains to the menopausal transition: a longitudinal study. |
| Q91222553 | The relative contributions of menopause and aging to postmenopausal osteoporosis |
| Q47278709 | The relative contributions of menopause and aging to postmenopausal reduction in intervertebral disk height |
| Q90165069 | The remains of the taboo: experiences, attitudes, and knowledge about menopause in the workplace |
| Q37610401 | The risk of stroke in postmenopausal women receiving hormonal therapy |
| Q34265642 | The role of antiandrogens in hormone replacement therapy. |
| Q38044746 | The role of cytokines in cardiovascular disease in menopause |
| Q38105358 | The role of cytokines in skin aging |
| Q38000317 | The role of gene expression profiling in the management of breast cancer patients |
| Q38717871 | The role of local estrogen therapy in the management of pelvic floor disorders |
| Q51544032 | The role of megestrol acetate as an alternative to conventional hormone replacement therapy. |
| Q36946810 | The role of menopausal hormone therapy in osteoporosis |
| Q38609082 | The role of menopausal hormone therapy in the management of osteoporosis |
| Q81681871 | The role of quantitative ultrasound in predicting osteoporosis defined by dual-energy X-ray absorptiometry in pre- and postmenopausal women |
| Q51364386 | The role of screening mammography in the era of modern breast cancer treatment. |
| Q48024942 | The role of self-rated health in the association between chronic somatic diseases and climacteric-related symptoms. |
| Q46014658 | The role of testosterone in women. |
| Q51410572 | The role of transvaginal ultrasound in screening for ovarian cancer. |
| Q83629917 | The role of vitamin D supplementation in HIV: an often forgotten perspective |
| Q95822723 | The safety of postmenopausal testosterone therapy |
| Q38109644 | The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China |
| Q103737579 | The severe acute respiratory syndrome due to coronavirus 2 (SARS-CoV-2) infection and the climacteric woman |
| Q46532011 | The silent grief: psychosocial aspects of premature ovarian failure |
| Q36946817 | The skin, carotid and intervertebral disc: making the connection! |
| Q45146531 | The stages of reproductive aging as proposed by workshops held in 2001 and 2010 (STRAW and STRAW + 10): a commentary. |
| Q36781520 | The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective |
| Q100950408 | The treatment of menopausal symptoms by traditional Chinese medicine in Asian countries |
| Q38586317 | The urogenital system and the menopause. |
| Q83966524 | The use and abuse of screening tests around menopause |
| Q49791687 | The use and discontinuation of hormone replacement therapy in women in South China |
| Q57180617 | The use of estradiol metered-dose transdermal spray in clinical practice |
| Q38011784 | The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. |
| Q97556855 | The use of hysteroscopy in endometrial cancer: old questions and novel challenges |
| Q59619147 | The use of isoflavinoids in menopausal health |
| Q40677988 | The use of proton pump inhibitors is positively associated with osteoporosis in postmenopausal women in Germany |
| Q45237508 | The usefulness of ovarian volume, antral follicle count and age as predictors of menopausal status |
| Q38407283 | The utility of measuring anti-Müllerian hormone in predicting menopause |
| Q48135320 | The validity of the Menopause-specific Quality of Life questionnaire in women with type 2 diabetes |
| Q95817706 | The value of repeat BMD testing in elderly people |
| Q64949803 | The view of The International Menopause Society on the Women's Health Initiative. |
| Q47291347 | The weight problem |
| Q45237505 | The women's health initiative reports in perspective: facts or fallacies? |
| Q37643712 | Therapeutic options for postmenopausal female sexual dysfunction. |
| Q44031524 | Three alternative ways to treat VMS failed |
| Q34536301 | Three midlife strategies to prevent cognitive impairment due to Alzheimer's disease |
| Q122443080 | Three-dimensional bioprinting of artificial ovaries by an extrusion-based method using gelatin-methacryloyl bioink |
| Q50856152 | Three-dimensional sonohysterography may replace hysteroscopy for women with perimenopausal bleeding. |
| Q78004628 | Thrombophilic profile of climacteric and menopausal women with venous thromboembolism |
| Q38133649 | Thyroid and menopause |
| Q57180616 | Thyroid disease in the perimenopause and postmenopause period |
| Q34294330 | Tibolone and its effects on bone: a review |
| Q56853912 | Tibolone and its effects on bone: a review |
| Q46683002 | Tibolone is not aromatized in postmenopausal women |
| Q80287824 | Time for evidence-based labelling of over-the-counter medicines |
| Q79747635 | Time for new long-term trials of postmenopausal hormone therapies! |
| Q91682605 | Time since menopause, but not age, is associated with increased risk of osteoporosis |
| Q40315288 | Time trends in breast cancer and menopause hormone therapy use in New Zealand |
| Q30456770 | Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model |
| Q51010786 | Tissue-specific effects of estrogen on glycerol channel aquaporin 7 expression in an ovariectomized mouse model of menopause. |
| Q40734535 | To be or not to be in sexual desire: the androgen dilemma |
| Q96119801 | To treat or not to treat? An evidence-based practice guide for the management of endometrial polyps |
| Q37360543 | Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview |
| Q37776520 | Topical vaginal estrogen therapy in managing postmenopausal urinary symptoms: a reality or a gimmick? |
| Q47239145 | Toward healthy aging through empowering self-care during the climacteric stage. |
| Q81604212 | Towards safer women, safer doses, safer routes and safer timing of administration of safer menopausal therapies |
| Q50119425 | Traditional Chinese medicine: perspectives on and treatment of menopausal symptoms |
| Q43006536 | Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns |
| Q43494612 | Transdermal hormone therapy and the risk of stroke and venous thrombosis |
| Q36084250 | Transdermal hormone therapy: gels and patches |
| Q44789973 | Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study |
| Q44018610 | Transvaginal color Doppler sonographic evaluation of the uterus in postmenopausal women on daily raloxifene therapy |
| Q82135493 | Treating menopausal symptoms with a complex remedy or placebo: a randomized controlled trial |
| Q28079287 | Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? |
| Q85508741 | Treatment failure in osteoporosis |
| Q61705886 | Treatment of atrophic vaginitis with topical conjugated equine estrogens in postmenopausal Asian women |
| Q77803029 | Treatment of estrogen deficiency symptoms in women surviving breast cancer |
| Q95806207 | Treatment of hypercholesterolemia - a revolution |
| Q90565487 | Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review |
| Q34437268 | Treatment of postmenopausal women with topical progesterone creams and gels: are they effective? |
| Q35772318 | Treatment of the genitourinary syndrome of menopause |
| Q49582420 | Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review |
| Q43232963 | Treatment persistence and compliance with a combination of calcium and vitamin D. |
| Q86582373 | Treatment with QiBaoMeiRan, a Chinese herbal formula, prevents bone loss in ovariectomized rat |
| Q39000948 | Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis |
| Q50236184 | Turner syndrome - growing pressure for more multidisciplinary clinics for adults and earlier diagnosis in children |
| Q50237604 | Turning the spotlight on lasers |
| Q43514886 | Type II diabetes mellitus and menopause: a multinational study |
| Q37610402 | Type and route of estrogen administration |
| Q39363360 | UK women doctors' use of hormone replacement therapy: 10-year follow up. |
| Q34447552 | Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues. |
| Q38261770 | Ultra-low dose - new approaches in menopausal hormone therapy. |
| Q46802787 | Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women |
| Q38429496 | Ultra-low-dose estradiol and norethisterone acetate: bleeding patterns and other outcomes over 52 weeks of therapy |
| Q39336361 | Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief |
| Q37206316 | Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy |
| Q38121156 | Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy |
| Q80204480 | Ultrasound appearance of the uterus in women over 60 years of age on tibolone: is it a SERM? |
| Q95840446 | Understanding systematic reviews and meta-analyses |
| Q38043486 | Understanding weight gain at menopause. |
| Q38106748 | Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. |
| Q48671400 | Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health |
| Q34142418 | Updated clinical recommendations for the use of tibolone in Asian women |
| Q45219310 | Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause |
| Q37456492 | Urogenital atrophy |
| Q36359543 | Urogenital effects of selective estrogen receptor modulators: a systematic review |
| Q40474001 | Use and perception of hormone therapy following media reports of the Women's Health Initiative: a survey of Australian WISDOM participants. |
| Q95412472 | Use of complementary and traditional medicine in the menopause |
| Q43691054 | Use of complementary medicinal therapies in West Pomerania: a population-based study |
| Q82359156 | Use of dietary supplements and medication among postmenopausal women with vasomotor symptoms |
| Q73341218 | Use of hormone replacement therapy by menopausal women in six family-practice teaching clinics in Israel |
| Q39175735 | Use of mindfulness, meditation and relaxation to treat vasomotor symptoms |
| Q38217340 | Use of ossein-hydroxyapatite complex in the prevention of bone loss: a review. |
| Q87294356 | Use of the levonorgestrel intrauterine system in postmenopause |
| Q30681302 | Using longitudinal data to define the perimenopause by menstrual cycle characteristics |
| Q99205054 | Uterine bleeding with hormone therapies in menopausal women: a systematic review |
| Q84687229 | Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy |
| Q77803102 | Uterine surveillance of asymptomatic postmenopausal women taking tamoxifen |
| Q91320122 | Uterine transplantation |
| Q50676926 | Uterotropic effects of dietary equol administration in ovariectomized Sprague-Dawley rats. |
| Q51366552 | VIP expression in vessels of the vaginal wall: relationship with estrogen status. |
| Q43669097 | Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey |
| Q88612201 | Vaginal Health: Insights, Views & Attitudes (VIVA-LATAM): results from a survey in Latin America |
| Q99638449 | Vaginal Health: Insights, Views & Attitudes survey in Latin America (VIVA-LATAM): focus on Brazil |
| Q30303078 | Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels |
| Q90846597 | Vaginal atrophy across the menopausal age: results from the ANGEL study |
| Q48261367 | Vaginal biological and sexual health--the unmet needs |
| Q43988748 | Vaginal cone for postmenopausal women with stress urinary incontinence: randomized, controlled trial. |
| Q35647630 | Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause |
| Q51382005 | Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. |
| Q48058845 | Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer |
| Q100377774 | Vaginal lubricants and moisturizers: a review into use, efficacy, and safety |
| Q88187167 | Vaginal progesterone and the vaginal first-pass effect |
| Q52975517 | Vaginal rugae: measurement and significance. |
| Q77430595 | Vaginal symptoms in Japanese postmenopausal women: comparison with other climacteric symptoms |
| Q48663992 | Validation of Italian version of the Women's Health Questionnaire: assessment of quality of life of women from the general population and those attending menopause centers |
| Q39352763 | Validation of osteoporosis risk assessment tools in middle-aged Thai women. |
| Q48037224 | Validation of the traditional Chinese version of the Menopausal Rating Scale with WHOQOL-BREF. |
| Q45774026 | Value of Osteoporosis Self-assessment Tools for Asians (OSTA) with or without Brown's clinical risk factors in detection of postmenopausal osteoporosis |
| Q51747429 | Value of transvaginal ultrasonography in endometrial evaluation of non-bleeding postmenopausal women. |
| Q44426065 | Vascular function of forearm microcirculation in postmenopausal women with type 2 diabetes: potential benefit of hormone replacement therapy? |
| Q79330258 | Vasoactive biomarkers and oxidative stress in healthy recently postmenopausal women treated with hormone replacement therapy |
| Q40704933 | Vasomotor symptoms and cardiometabolic risk factors in menopausal women: a MONET Group study |
| Q37919099 | Vasomotor symptoms and cardiovascular disease risk |
| Q37610378 | Vasomotor symptoms and cardiovascular risk |
| Q83394775 | Vasomotor symptoms and negative affect |
| Q38266415 | Vasomotor symptoms and urogenital atrophy in older women: a systematic review. |
| Q46877649 | Vasomotor symptoms decrease in women with breast cancer randomized to treatment with applied relaxation or electro-acupuncture: a preliminary study |
| Q91589272 | Vasomotor symptoms in aging Chinese women: findings from a prospective cohort study |
| Q39269760 | Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? |
| Q39179291 | Vasomotor symptoms in prostate cancer survivors undergoing androgen deprivation therapy |
| Q49484057 | Vasomotor symptoms: natural history, physiology, and links with cardiovascular health |
| Q83966570 | Villous papyraceous: an unusual cause of tamoxifen-induced postmenopausal bleeding |
| Q82131870 | Visceral fat accumulation and cardiovascular disease risk profile |
| Q44624268 | Vitamin C improves endothelial function in healthy estrogen-deficient postmenopausal women |
| Q38247395 | Vitamin D and health issues--questioned benefits |
| Q43929263 | Vitamin D receptor and estrogen receptor gene polymorphisms in postmenopausal Danish women: no relation to bone markers or serum lipoproteins |
| Q46226825 | Vitamin D receptor gene and risk of fracture in postmenopausal women: a meta-analysis |
| Q54382643 | Vitamin D receptor gene polymorphisms in a group of postmenopausal Turkish women: association wıth bone mineral density. |
| Q90209057 | Vitamin D restriction enhances periovarian adipose tissue inflammation in a model of menopause |
| Q92332701 | Vitamin D supplementation improves the metabolic syndrome risk profile in postmenopausal women |
| Q91314912 | Vitamin D, menopause, and aging: quo vadis? |
| Q37801923 | Vitamin D: a hormone for all seasons. |
| Q95787706 | Vitamins and bone health in women |
| Q39161834 | Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions. |
| Q36762551 | Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey |
| Q92615788 | Vulvovaginal atrophy in women after cancer |
| Q48097089 | Vulvovaginal atrophy--a tale of neglect |
| Q91963765 | Vulvovaginal graft-versus-host disease: a review |
| Q79954318 | WHI and breast cancer: a response to a recent publication from the WHI |
| Q84485150 | WHI dietary modification trial – disappointing results? |
| Q81317125 | WHI, WHI, WHI? |
| Q35081421 | WISDOM: history and early demise - was it inevitable? |
| Q48030213 | Water- versus land-based treatment for postural control in postmenopausal osteoporotic women: a randomized, controlled trial. |
| Q46089118 | Weight gain and abdominal obesity at menopause |
| Q47190100 | Weight gain and the menopause: a 5-year prospective study |
| Q37988600 | Weight loss, weight regain and bone health |
| Q44982979 | Well-being at onset of hormone replacement therapy: comparison between two continuous combined regimens |
| Q44955633 | Wenshen Xiaozheng Tang suppresses the growth of endometriosis with an antiangiogenic effect |
| Q37964796 | What are the real risks for breast cancer? |
| Q37672629 | What can be done about hot flushes after treatment for breast cancer? |
| Q92093701 | What can we learn from the vaginal mesh story? |
| Q95780567 | What if? |
| Q86691404 | What influences the age of menopause? |
| Q89464348 | What is scientific truth? |
| Q51636384 | What is the best equation to estimate the basal energy expenditure of climacteric women? |
| Q38253001 | What is the influence of cyclooxygenase-2 on postmenopausal endometrial polyps? |
| Q93053568 | What is the position of testosterone in the care of women? |
| Q88047558 | What is the right dose of modern medicine? |
| Q39067032 | What is the role of bariatric surgery in the management of obesity? |
| Q34990455 | What is tibolone--and is it a SPEAR? |
| Q38998681 | What is wrong with the medical literature? |
| Q93210509 | What should guide our patient management of vulvovaginal atrophy? |
| Q48070650 | What the future holds for women after menopause: where we have been, where we are, and where we want to go. |
| Q99546369 | What's in a name? Eponyms, acronyms and POI |
| Q37995320 | What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone |
| Q84937995 | When will the WHI investigators acknowledge what they are saying? |
| Q95840456 | When you are making plans to publish research, you need to plan for data sharing |
| Q31044049 | Where is the evidence for effectiveness of treatments for the menopause? Introducing the Cochrane Collaboration |
| Q77811554 | Which is the appropriate hormone replacement therapy after sub-total hysterectomy? |
| Q52150113 | White matter hyperintensities, hot flushes and estrogen--are they related? |
| Q97556846 | Why are you reading about study design in Climacteric? |
| Q94958915 | Why do we need cohort studies? |
| Q36561356 | Why is cardiovascular health important in menopausal women? |
| Q90710512 | Will estradiol/progesterone capsules for oral use become the best choice for menopausal hormone therapy? |
| Q40802080 | Withdrawal of hormone therapy and increased risk of cardiovascular disease |
| Q92593241 | Women and diabetes: disparity in treatment |
| Q51136922 | Women's expectations and experiences of hormone treatment for sexual dysfunction. |
| Q39898939 | Women's mid-life health experiences in urban UK: an international comparison |
| Q80287837 | Women's needs for CAM information to manage menopausal symptoms |
| Q39942384 | Women's perception of the menopause and hormone treatment: barriers against hormone therapy |
| Q33213520 | Women's perceptions of hormone replacement therapy: risks and benefits (1980-2002). A literature review. |
| Q89988588 | Women's perspectives of early menopause: development of a word cloud |
| Q91955833 | Women's rights in Asia and elsewhere - a fact or an illusion? |
| Q48629369 | Working towards global recommendations to governments to optimize women's midlife health |
| Q38399321 | Working women and the menopause |
| Q38847585 | World-wide architecture of osteoporosis research: density-equalizing mapping studies and gender analysis. |
| Q100441792 | Xiangshao granules can relieve emotional symptoms in menopausal women: a randomized controlled trial |
| Arabic (ar / Q13955) | مجلة سن اليأس | wikipedia |
| Climacteric | wikipedia | |
| Climacteric (journal) | wikipedia | |
| ml | ക്ലൈമാക്റ്ററിക് (ജേണൽ) | wikipedia |
Search more.